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Endoplasmic Reticulum (ER) associated degradation (ERAD) is the general process in which 
misfolded secretory proteins are monitored and degraded to protect the cell from a buildup of 
nonfunctioning proteins. Apolipoprotein B (ApoB), an ERAD substrate is a large hydrophobic 
secretory protein associated with the transport of lipids and cholesterol by lipoproteins in the 
body.  ApoB synthesis involves cotranslational translocation through the Sec61 translocon into 
the ER. If properly folded and lipidated, ApoB is then retrotranslocated through the same pore.  
Since ApoB contains many aggregation-prone hydrophobic β-sheets, what prevents ApoB 
aggregation before degradation by ERAD?  Initial considerations suggested that cytosolic 
factors, such as lipid droplets or chaperone “holdases,” “foldases,” and “disaggregases” may help 
to maintain ApoB’s solubility post retrotranslocation.  To test this hypothesis, I adapted our yeast 
galactose inducible ApoB expression system to be β-estradiol inducible and used it to investigate 
various chaperone candidates to determine if they affect ApoB stability.  Upon large scale 
isolation of lipid droplets, ApoB was found not to interact with lipid droplets.  Next, I 
investigated potential chaperones.  I found that the small heat shock proteins, a family of ATP-
independent chaperones, and the TRiC complex, an Hsp60 family member, do not affect ApoB 
stability. However, I determined that Hsp104, a AAA+ ATPase which helps to refold and 
reactivate aggregated proteins, is a pro-degradation factor for ApoB.  ApoB degradation was 
slowed in the absence of this chaperone while overexpression caused faster degradation.  I then 
investigated Rvb2, the yeast homolog of the human functional analog of Hsp104, to determine its 
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effect on ApoB stability.  Unexpectedly, Rvb2 did not restore ApoB degradation in the absence 
of Hsp104.  Together, my data indicate that ApoB does require chaperone disaggregase function 
prior to ERAD.   
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1.0  INTRODUCTION 
Cardiovascular disease is a serious concern for human health, affecting nearly one third of all 
people.  Hence, understanding the molecular defects underlying this disease is necessary for the 
development of therapeutics to combat this condition.  One hallmark of cardiovascular disease is 
the overabundance of circulating cholesterol, which can build up on artery walls.  Current 
treatments mainly focus on the use of statins, which block cholesterol synthesis.  However, 
recent efforts to find alternative treatments for this condition have been focused on several 
factors including Apolipoprotein B (ApoB), a protein required for cholesterol delivery 
throughout the body.  Therefore, understanding ApoB regulation is essential to identify 
alternative therapies for cardiovascular diseases. 
 ApoB protein levels are metabolically regulated by endoplasmic reticulum (ER) 
associated degradation (ERAD) as well as post ER degradation.  ERAD is a cellular quality 
control mechanism, which monitors secretory proteins and selectively degrades misfolded 
substrates.  By investigating how ERAD monitors and degrades ApoB, we can potentially 
identify new drug targets to treat cardiovascular disease.  In this chapter, I discuss the severity of 
cardiovascular disease affecting humans.  I further discuss how cholesterol is regulated and how 
it is delivered to peripheral tissues.  Finally, a discussion of the current knowledge of ApoB 
biosynthesis and its degradation is presented.     
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1.1 CARDIOVASCULAR DISEASE 
1.1.1 Statistics and Significance 
Cardiovascular disease is one of the leading causes of death worldwide, accounting for 31% of 
all deaths (Roth et al, 2015).  In the United States, this disease is responsible for more deaths 
than the next two conditions, cancer and chronic lower respiratory disease, combined.  Except 
for 1918 due to influenza, cardiovascular disease has been the leading cause of death worldwide 
every year since 1900, (Roger et al, 2011).  The most recent report from the American Heart 
Association estimates that 1 in 3 people will be affected by some form of cardiovascular disease 
in their lifetime and will result in the deaths of approximately 800,000 Americans annually.  This 
is about 2,200 people per day or 1 death every 40 seconds.  It is no surprise that a better 
understanding of pathways to combat this disease are imperative.   
It is estimated that ~92 million Americans are currently living with some form of 
cardiovascular disease (Benjamin et al, 2017; Farvid et al, 2014).  Furthermore, many Americans 
are at risk for developing some form of cardiovascular disease or are living with undiagnosed 
conditions.  Cardiovascular disease encompasses a variety of disorders that affect the 
cardiovascular system and the heart.  These conditions include stroke, heart disease, heart 
defects, diabetes, high cholesterol, high blood pressure, arrhythmias, arterial disease, and 
coronary artery disease.  Coronary artery disease (CAD) is the most prevalent form of 
cardiovascular disease.  Its levels have been steadily increasing from 20% of all cases in 2011 to 
the current level of 45% (Benjamin et al, 2017; Caffrey et al, 2011; Mensah et al, 2005; Roger et 
al, 2011).  Stroke is the second most common condition, accounting for 16.5% deaths (Fang et 
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al, 2014; Ovbiagele et al, 2013).  The third most prevalent condition, heart disease, accounts for 
8.5% of cardiovascular disease related deaths (Farvid et al, 2014).   
High levels of cholesterol aggravate cardiovascular risk. Reducing cardiovascular risk 
can be accomplished by exercise and alterations to diet.  In fact through a meta-analysis study of 
over 120,000 people, as little as 15 minutes of moderate exercise reduce mortality rates by 22% 
in adults 60 years old and over (Hupin et al, 2015).  However, 1 in 3 adults do not regularly 
perform the recommended 60 minutes of physical activity per day (Benjamin et al, 2017).  
Although the percentage of U.S adults who eat a healthy diet rose to 1.5% of Americans, the 
prevalence of obesity has risen from 30 to 37% of Americans in the same time frame (Flegal et 
al, 2016; Lloyd-Jones et al, 2010; Ogden et al, 2015; Rehm et al, 2016).  Moreover, 12% of 
Americans have high cholesterol levels and 40% of Americans are living with borderline high 
cholesterol levels (Benjamin et al, 2017; Carroll et al, 2015; National Institutes of Health, 2012).   
 
1.1.2 Coronary Artery Disease Pathology 
CAD is characterized by atherosclerosis, which is linked to the presence of atherosclerotic 
plaques (see below).  These plaques can accumulate on artery walls, which lead to inflammation 
via the generation of oxidized lipids (Han & Kaufman, 2016; Mozzini et al, 2017).  As the 
plaques continue to grow, they reduce the artery diameter and restrict blood flow, forcing the 
heart to work harder to pump blood throughout the body.  Parts of these plaques can potentially 
break off and enter the bloodstream, circulate to other areas of the body to cause heart attack or 
stroke if the plaque-derived particles reach the heart or brain (Insull, 2009; Stefanadis et al, 
2017).   
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As noted above, plaques can trigger an inflammatory response due to the presence of 
oxidized lipids.  The oxidized lipids cause the surrounding epithelial cells to secrete 
inflammatory signals, including adhesion molecules, chemokines, growth factors, and possibly 
NFκB, which recruit monocytes and lymphocytes to the artery (Boring et al, 1998; Collins et al, 
2000; Deng et al, 2004; Dong et al, 1998; Gu et al, 1998; Hotamisligil, 2010; Shih et al, 1999; 
Watson et al, 1997).  Oxidized lipids may also reduce the amount of generated nitrous oxide, 
further inhibiting the ability of the vasculature to widen.  Furthermore, recent studies observed 
the upregulation of BiP, a marker of the unfolded protein response, and CHOP, a signal related 
to activation of the autophagy pathway and cellular apoptosis, in peripheral blood mononuclear 
cells in patients with CAD.  These results strongly suggest that the vasculature is altered in CAD 
patients (Knowles et al, 2000; Lusis, 2000; Mozzini et al, 2017; Mozzini et al, 2014; Thorp et al, 
2009).   
Plaques are primarily derived from low density lipoproteins (LDLs) that are highly 
enriched in cholesterol and Apolipoprotein B (ApoB) (Fisher, 2016; Tiwari & Siddiqi, 2012).  
As described below, ApoB is the major structural component of LDL particles and is required for 
their formation (see section 1.3.2).  Although LDL particles are taken up by macrophages, these 
cells sequester large amounts of cholesterol and ApoB in LDLs rather than digesting them.  
Ultimately, such macrophages become stuck on the arterial wall (Fisher, 2016; Kwiterovich, 
2000).  Other lipoprotein remnants, including those derived from very low density lipoproteins 
(see section 1.2.2), can then adhere to the vasculature wall, associating with the lipoproteins that 
are already present on the arterial wall.  As these plaques aggregate, the rate of macrophage/LDL 
uptake and arterial association accelerate, which further impairs blood flow and increases the risk 
of heart attack and stroke.   
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1.1.3 Methods to Combat Coronary Artery Disease 
Not surprisingly, devising treatments for cardiovascular diseases is an active area of research.  
Prescribed to nearly 40% of Americans, the most common treatment is the use of statins. Statins 
are a class of drugs that inhibit cholesterol synthesis by acting as competitive inhibitors of 3-
hydroxy-3-methyl-glutaryl coenzyme A (Hmg CoA) reductase (Saeedi Saravi et al, 2017; Sikka 
et al, 2011).  This prevents the conversion of Hmg CoA to mevalonate, which is a precursor to 
cholesterol and represents the rate limiting step for cholesterol biosynthesis (Bucher et al, 1960).  
These drugs can reduce LDL associated cholesterol levels up to 60% at the highest doses 
(Boekholdt et al, 2014; Stone et al, 2014; Weber et al, 2017).  Reducing LDL cholesterol levels 
through statin use can prevent up to 25% of sudden cardiovascular related events (Baigent et al, 
2010).    Combined with Ezetimibe, a drug which prevents cholesterol uptake by inhibiting the 
activity of Niemann-Pick C1-like protein 1 (NPC1L1), statin treatment is enhanced by a further 
6.4% in reducing LDL levels (Cannon et al, 2015).  NPC1L1 is a multispan membrane protein, 
localized to the surface of enterocytes, which binds lipids through its sterol sensing domain.  The 
protein is rapidly internalized in the presence of dietary cholesterol and fatty acids, and 
Ezetimibe blocks NPC1L1 internalization to prevent cholesterol uptake (Chang & Chang, 2008; 
Davies et al, 2000; Garcia-Calvo et al, 2005; Ge et al, 2008; Yu et al, 2006). 
Although statins remain an attractive and well established first-line compound to reduce 
the amount of cholesterol synthesized in the body and have been used for 30 years, they are not 
without complications (Endo, 2010).  First, statins are no universally effective.  In a meta-
analysis of over 38,000 patients, Boekholdt and coworkers discovered that statin effectiveness 
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varied significantly among users and that, more than 40% of patients undergoing high dose statin 
therapy did not achieve an optimal level of circulating cholesterol (Boekholdt et al, 2014).  
Moreover, certain patients simply do not respond to statin therapy, possibly due to genetic 
variation, or the statins cannot be combined with other drugs the patients are concurrently taking 
(Dadu & Ballantyne, 2014; Sikka et al, 2011).  Genetic variation is often due to polymorphisms 
in genes related to statin metabolism, including intestinal P-glycoprotein, organic anion 
transporter 2, coenzyme Q10, and cytochrome P450 3A4 (Baker & Samjoo, 2008; Fiegenbaum 
et al, 2005; Frudakis et al, 2007; Link et al, 2008; Mulder et al, 2001; Oh et al, 2007; Zuccaro et 
al, 2007).  Due to these deficiencies and the observed side effects, it is crucial that alternative 
therapies are identified to control cholesterol production.  Second, it is estimated that 25-30% of 
patients discontinue statin use to due side effects (Raju et al, 2013; Rosenson, 2016).  The most 
common side effects of statin therapy, affecting approximately 15% of patients, include muscle 
wasting, leg cramps, and myopathy (Dadu & Ballantyne, 2014; Fitchett et al, 2015; Mancini et 
al, 2013).  Although many of these relatively minor side effects disappear by simply switching to 
a different statin, other more serious side effects can occur, such as acute liver failure and 
peripheral neuropathy (Sikka et al, 2011).  Third, a meta-analysis identified a 9% increase in the 
incidence of diabetes associated with statin use (Preiss et al, 2011; Weber et al, 2017).   
Recently, antibody therapies have been considered to control circulating cholesterol 
levels.  The most promising therapy is one developed against proprotein convertase 
subtilisin/kexin type 9 (PCSK9), a serine protease of the proprotein convertase superfamily 
(Narasimhan, 2017; Schulz & Schluter, 2017; Weber et al, 2017). In humans, PCSK9 targets the 
LDL receptor for degradation via autophagy through a mechanism that has not been fully 
elucidated (Narasimhan, 2017; Schulz & Schluter, 2017).  By inhibiting PSCK9, more LDL 
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receptors are present on the cell surface to bind ApoB (see below), therefore reducing circulating 
LDLs.  These antibodies  reduce LDL levels by up to 60%, and two antibody therapeutics, 
Evolocumab and Alirocumab, were recently approved as a treatment in the absence of a large 
scale study for specific patient groups (Okopien et al, 2016; Robinson et al, 2015; Weber et al, 
2017; Zhang et al, 2015).  The initial trials followed over 27,000 patients for 2 years and 
investigated if Evolocumab in combination with statins had additional value compared to statins 
alone.  Patients taking both drugs saw a 59% reduction of LDL cholesterol, with no increase of 
side effects (Narasimhan, 2017; Sabatine et al, 2017).  While anti-PCSK9 therapy  may be a 
promising strategy for treating CAD, further investigation into alternative therapeutic strategies 
is necessary as these antibodies are cost prohibitive and are thus far approved only for specific 
patient groups (Weber et al, 2017).   
The next most promising alternative therapy for treating CAD is reducing ApoB levels.  
As discussed in section 1.2.1, ApoB is the main structural component of lipoproteins, which 
deliver cholesterol to the peripheral tissues (Fisher, 2016).  In peripheral tissues, ApoB binds to 
the LDL receptor, which is then endocytosed and routed to the lysosome.  The internalized ApoB 
is degraded but the cholesterol and cholesterol esters are stored and used by the host cell (Brown 
& Goldstein, 1975; Brown & Goldstein, 1976).  One such method to reduce ApoB levels is via 
anti-sense oligonucleotides, which target the ApoB message and down regulate protein levels 
(Liscinsky, 2013; Ricotta & Frishman, 2012; Thomas & Ginsberg, 2010; Wong & Goldberg, 
2014).  Mipomersen is the first ApoB-specific anti-sense oligonucleotide treatment approved for 
use in humans (Kynamro, 2013).  Prior to its approval in 2013, phase 3 clinical trials indicated a 
reduction in LDL cholesterol of 25-40% (McGowan et al, 2012; Raal et al, 2010).  However, 
Mipomersen is also only approved for specific patients, i.e., those suffering from familial 
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hypercholesteremia, which most often arises from mutations in the LDL receptor.  These 
mutations either lower LDL receptor populations in the cell or prevent the plasma membrane 
resident LDL receptor from clearing LDLs from the serum (Austin et al, 2004; Brown & 
Goldstein, 1975; Brown & Goldstein, 1976; Lister Hill National Center for Biomedical 
Communications, 2017).  Furthermore, Mipomersen has not been approved for use in Europe 
due to concerns with liver toxicity and cardiovascular complications (Liscinsky, 2013; Okopien 
et al, 2016; Weber et al, 2017; Wong & Goldberg, 2014).   Further investigation is undoubtedly 
required to understand the long term effects of this drug in humans.  
Recently, small molecule inhibitors have been developed to treat CAD.  One such drug, 
Lomitapide, prevents lipid loading onto ApoB, which subsequently reduces cholesterol delivery.  
Lomitapide inhibits the microsomal triglyceride transfer protein (MTP) complex, which loads 
cholesterol, cholesterol esters, triglycerides, and phospholipids onto ApoB in the liver (see 
section 1.2.2).  Lomitapide treatment lowered triglyceride levels by 65% and LDL levels by 50% 
(Cuchel et al, 2013).  However, Lomitapide is only approved for homozygous familial 
hypercholesterolemia patients, has severe side effects, and may cause liver damage and steatosis 
(Roeters van Lennep et al, 2015; Weber et al, 2017).   
Another promising drug target to reduce the incidence of CAD is the cholesteryl ester 
transfer protein (CETP). CETP transfers cholesterol from high density lipoproteins (HDLs) to 
ApoB-containing lipoproteins, thus inducing reverse cholesterol transport, which is the 
movement of cholesterol from peripheral tissues to the liver (see section 1.2.1) (Shapiro & Fazio, 
2017; Weber et al, 2017).  Thus, it was predicted that CETP inhibition would lower cholesterol 
levels.  However during clinical trials, severe complications arose, including off target effects 
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which lead to increased death rates in high risk patients and no obvious effects on lipid levels 
(Barter et al, 2007; Kastelein et al, 2015; Okopien et al, 2016; Schwartz et al, 2012). 
The relationship between CAD and autophagy is another area of therapeutic interest. As 
described in greater detail below (section 1.6), autophagy is the pathway in which aggregated 
proteins, organelles, and specific cytoplasmic proteins become sequestered into double 
membranous vesicles in the cytoplasm, which are then engulfed by the lysosome and degraded 
(Levine & Klionsky, 2017; Levine & Kroemer, 2008; Yin et al, 2016).  TFEB, an activator of 
autophagy, stimulates the degradation of lipids and fatty acids in the lysosome (Sardiello et al, 
2009; Settembre et al, 2011).  This phenomenon led to the discovery that overexpression of 
TFEB induced cholesterol removal, as well as the degradation of ubiquitinated proteins 
(Emanuel et al, 2014).  Moreover, TFEB overexpression not only increased degradation of 
aggregated proteins associated with p62, an autophagy receptor/chaperone but also reduced 
inflammatory signaling, resulting in smaller atherosclerotic plaques (Sergin et al, 2017).    
Current studies in patients with non-alcoholic fatty liver disease are being undertaken to 
determine if polymorphisms in autophagy related genes affect lipid storage (Yu-Cheng Lin, 
2017).     
Although many CAD treatments seek to reduce cholesterol levels, it should be noted  that 
cholesterol synthesis cannot be completely halted.  Cholesterol is an important component of cell 
membranes, facilitates membrane curvature and fusion, and is a biosynthetic precursor to 
multiple cellular factors, including bile acids, vitamins, sterols, and hormones (Churchward et al, 
2005; Simons & Ikonen, 2000; Simons & Vaz, 2004; Stevenson et al, 2016).  The absence of 
cholesterol stunts growth and development, and results in diseases such as abetalipoproteinemia 
and familial hypobetalipoproteinemia.  Familial hypobetalipoproteinemia affects ~1 in 1000-
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3000 individuals and abetalipoproteinemia has 100 confirmed cases worldwide (Schonfeld et al, 
2005; Zamel et al, 2008).  Familial hypobetalipoproteinemia most often arises from mutations in 
ApoB while abetalipoproteinemia is due to the inability of the MTP complex to load lipids onto 
ApoB.  Both of these conditions cause extremely low levels of circulating vLDLs (in the 5th 
percentile or less) and serum cholesterol (Schonfeld et al, 2005; Wetterau et al, 1992).  While 
these diseases are rare, they can result in ataxia, neurological defects, and improper growth and 
development (Medicine, 2017a; Medicine, 2017b; Schonfeld et al, 2005; Zamel et al, 2008).  
Therefore, cholesterol levels must be tightly regulated to maintain proper homeostasis.   
Thus, too much cholesterol results in cardiovascular diseases while too little cholesterol 
results in a host of other problems.  As discussed above, drugs against multiple targets, including 
PCSK9 and ApoB, have been investigated, but in each case there are limitations to these 
treatments.  Are there other ways to specifically target the levels of cholesterol?  Identifying 
novel factors which contribute to the regulation of ApoB levels might represent new treatments 
for CAD. 
1.2 LIPOPROTEINS 
1.2.1 Classes of Lipoprotein Particles 
Lipoproteins particles are responsible for the transport of cholesterol, cholesteryl esters, and, 
triacylglycerols throughout the body.  Lipoproteins are composed of a phospholipid outer layer 
surrounding a neutral lipid inner core (Dominiczak & Caslake, 2011).  There are four main 
classes of lipoproteins: HDLs, LDLs, very low density lipoproteins (vLDLs), and chylomicrons 
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(Figure 1).  These lipoproteins are classified based on density and size.  HDLs are the most dense 
particles, with a density of 1.063-1.210 g/mL, while chylomicrons are the least dense, with a 
density of less than 0.95 g/mL (Christie, 2014; Cox & Garcia-Palmieri, 1990; Dominiczak & 
Caslake, 2011; Wasan et al, 2008).  Each class has a distinct diameter, ranging in size from 5 nm 
to 1000 nm, with diameter size inversely related to density (Cox & Garcia-Palmieri, 1990; 
Wasan et al, 2008).    
Apolipoproteins provide structural rigidity by serving as a scaffold for growing 
lipoproteins.  Apolipoproteins are amphipathic proteins that provide structural support and act as 
detergents and as receptors.  They also regulate the enzymes involved in neutral lipid synthesis 
and can be transferred between lipoproteins (Dominiczak & Caslake, 2011; Wasan et al, 2008).  
At least 10 apolipoproteins are found in human blood plasma.  ApoB is associated with 
cholesterol delivery, and ApoB isoforms are present in LDLs, vLDLs, and chylomicrons.  ApoB 
provides the backbone for the growing lipoprotein particle during synthesis and subsequently 
during maturation and modification, and contains a recognition motif for the LDL receptor 
(Dominiczak & Caslake, 2011; Wasan et al, 2008).  Interestingly, LDLs, vLDLs, and 
chylomicrons each contain only 1 molecule of ApoB, representing the sole source of protein 
(Cladaras et al, 1986).  ApoB is also the only essential apolipoprotein and is non-exchangeable 
(see section 1.4).  However, other lipoproteins contain exchangeable apolipoproteins, such as 
apolipoprotein AI, CI, CII, CIII, and E (Dominiczak & Caslake, 2011; Wasan et al, 2008).   
Cholesterol not only needs to reach peripheral tissue but also needs to be recycled.  This 
is accomplished by HDLs, which are responsible for reverse cholesterol transport in the body 
(Wasan et al, 2008).  During this process, primordial HDLs are made in the liver and intestine, 
and primarily contain the exchangeable apolipoproteins, mainly apoAI and AII (Dominiczak & 
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Caslake, 2011; Wasan et al, 2008).  In turn, HDLs receive free fatty acids from peripheral tissues 
and esterify the fatty acids with cholesterol through the lecithin-cholesterol acyl transferase 
(LCAT) and ApoAI.  The HDLs can then return to the liver and interact with the HDL receptor 
for cholesterol internalization (Acton et al, 1996; Chau et al, 2006).  However, only about half of 
the cholesterol is delivered to the liver while the other half will be transferred to ApoB-
containing lipoproteins by cholesteryl ester transferases, which append triglycerides onto 
cholesterol (Kwiterovich, 2000; Wasan et al, 2008).  These molecules may be stored in the liver 
or are reinserted into LDL particles.    
1.2.2 Very Low Density Lipoprotein Maturation and Secretion  
LDLs, vLDLs, and chylomicrons are responsible for transporting the majority of fatty acids, 
triacylglycerol, and cholesterol to peripheral tissues in a highly controlled and regulated process.  
Primordial vLDLs are initially synthesized in the endoplasmic reticulum (ER) on membrane 
bound ribosomes as ApoB is translocated into the ER through a proteinaceous channel.  As a 
result, ApoB is cotranslationally lipidated by the MTP complex in the ER (Mitchell et al, 1998).  
The MTP complex consists of an “M” subunit and a molecule of protein disulfide isomerase 
(PDI).  The M subunit is required for lipid transfer while PDI facilitates disulfide bond formation 
and acts as a chaperone during vLDL synthesis, allowing ApoB  incorporation into the pre-vLDL 
particle (Lamberg et al, 1996; Wetterau et al, 1991a; Wetterau et al, 1991b; Wetterau et al, 
1990).  These primordial vLDL particles are secreted in non-canonical COPII coated vesicles, 
which are larger than normal COPII coated vesicles (Gusarova et al, 2003; Tiwari & Siddiqi, 
2012).   
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Figure 1. Lipoprotein Particles of Blood Plasma. 
The four main classes of plasma lipoproteins are HDLs, LDLs, vLDLs, and 
chylomicrons.  HDLs are the smallest particles and are the most dense.  Chylomicrons are the 
largest particle and are the least dense.  LDLs and vLDLs contain ApoB100 as their major 
apolipoprotein while chylomicrons in humans contain ApoB48.  HDLs contain ApoAI and 
ApoAII as the major apolipoprotein.  VLDLs are synthesized in the liver while chylomicrons are 
synthesized in the small intestine.  LDL is a product of VLDL modifications made in circulation.  
HDLs are made in both tissues.   
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The COPII coat is a 5 member complex, consisting of the Sar1 GTPase, Sec23, Sec24, Sec13, 
and Sec31, which mediate transport of cargo from the ER to the Golgi (Baker et al, 1988; 
Barlowe et al, 1994; Kuge et al, 1994; Lord et al, 2013; Rothman & Wieland, 1996; Ruohola et 
al, 1988).  It has been recently proposed that TANGO, a receptor for pre-collagen (another large 
secretory protein), and its partner TALI recruit lipids to ER exit sites to facilitate pre-vLDL 
secretion (Santos et al, 2016).  Regardless of the mechanism, these pre-vLDL particles exit the 
ER and traffic next to the Golgi apparatus.    
In the Golgi, the pre-vLDL particles are further lipidated and ApoB undergoes 
posttranslational modifications and conformational changes which result in the mature vLDL 
particle (Fisher & Ginsberg, 2002; Ginsberg & Fisher, 2009; Gusarova et al, 2003; Gusarova et 
al, 2007).  After exiting the Golgi, these particles enter the blood stream and migrate to 
peripheral tissues.  Upon reaching epithelial cells in peripheral tissue, the ApoCII component 
activates lipoprotein lipase on the cell surface.  Through its hydrolytic activity, lipoprotein lipase 
releases free fatty acids and triacylglycerol, which can be taken up into the epithelial cells that 
line the blood stream.  These molecules are in turn oxidized for ATP production or stored for 
future energy requirements (Dominiczak & Caslake, 2011; Kwiterovich, 2000).   
 Due to the reduced amount of triacylglycerol, the vLDL particle is now considered an 
LDL particle and must be recycled or can be used to transfer cholesterol to peripheral tissues.  To 
this end, the LDL now exposes a C-terminal domain in ApoB which contains the recognition site 
for the LDL receptor (Boren et al, 1998).  As noted above, this allows for receptor mediated 
endocytosis of LDL into tissues.  After the LDL containing endocytic vesicles fuse with the 
lysosome and release their contents, cholesterol and triglycerides are produced from cholesteryl 
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esters and ApoB is degraded by the proteinases that reside in the lysosome (Brown & Goldstein, 
1975; Brown & Goldstein, 1976; Kwiterovich, 2000).   
1.3 APOLIPOPROTEIN B 
1.3.1 Isoforms 
ApoB is transcribed from a single 45 kb gene which results in two naturally occurring isoforms.  
This single transcript creates the ~550 kDa full length ApoB protein, known as ApoB100, as 
well as an isoform that contains the N-terminal 48% of ApoB, termed ApoB48  (Hussain et al, 
2003; Wasan et al, 2008).  To produce either isoform, the ApoB transcript is produced as one 15 
kb mRNA.  In the small intestine, where ApoB48 is required for chylomicron formation, the 
ApoB mRNA editing complex-1 (ApoBEC-1) is expressed.  ApoBEC-1 is the founding member 
of a large family of RNA editing enzymes that deaminate nucleotides (Blanc & Davidson, 2010; 
King & Larijani, 2017; Salter et al, 2016).  Specifically, ApoBEC-1 deaminates the ApoB100 
mRNA at codon 2153.  This results in a change from a CAA to UAA, which converts a 
glutamine into a stop codon in the mRNA transcript (Blanc & Davidson, 2010; Fisher & 
Ginsberg, 2002; Giannoni et al, 1994; Hadjiagapiou et al, 1994).  Once translated, this edited 
transcript produces a protein which contains the N-terminal 48% of ApoB100 (i.e. ApoB48). 
Interestingly, ApoB, the only non-exchangeable apolipoprotein, is essential for 
lipoprotein synthesis (Gretch et al, 1996; Hussain et al, 2003; Segrest et al, 1992).  In fact, a 
homozygous knockout of ApoB resulted in embryonic lethality in mice, whereas heterozygous 
knockout mice developed normally but were protected from hypercholesteremia (Farese et al, 
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1995).  Remarkably, over 100 coding and non-coding polymorphisms have been identified in 
APOB and several may cause disease (Benn et al, 2005; Dominiczak & Caslake, 2011).  A 
familial defective form of ApoB arises from a glutamine to arginine substitution  at codon 3500, 
which reduces ApoB’s ability to interact with the LDL receptor, affecting ~1 in 500 Caucasians 
(Innerarity et al, 1990).  In contrast, a rare arginine to proline substitution mutation at codon 
3480, which may affect the α-helical region in which the amino acid resides, results in 
hypobetalipoproteinemia (Benn et al, 2005).  Two other common substitutions are found in the 
signal peptide, which affect the ability of ApoB to enter the ER and ultimately be secreted in 
lipoprotein particles (Blackhart et al, 1986; Sturley et al, 1994). 
Another mutation in the ApoB gene results in a truncated protein at codon 1305 by  
generating a premature stop codon due to a C to T nucleotide transition (Collins et al, 1988; 
Huang et al, 1989).  Even though the resulting protein harbors only the N-terminal 29% of 
ApoB, lipids still associate with ApoB but lipid poor vLDL particles are produced.  This 
“ApoB29” protein traffics through the secretory pathway as efficiently as larger ApoB variants, 
but smaller sized lipoprotein particles are evident (Linton et al, 1993; McLeod et al, 1994).  
Individuals expressing this mutated protein suffer from hypobetalipoproteinemia (Collins et al, 
1988). 
1.3.2 Structural Features 
As ApoB is the main structural component of lipoproteins, it must interact with hydrophobic 
cholesterol, cholesterol esters, phospholipids, and triacylglycerol molecules to form a lipoprotein 
particle.  However, ApoB must also be able to function in the aqueous environment of blood 
plasma.  Although a crystal structure is currently unavailable, ApoB is believed to contain 
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multiple α-helical domains which give rise to its amphipathic nature (Figure 2).  Based on 
computer predictions, ApoB is over 25% α-helical, which,  is common to the exchangeable 
apolipoproteins (De Loof et al, 1987; Gotto et al, 1968; Scanu & Hirz, 1968; Singh & Lee, 1986)  
ApoB is targeted to and translocates into the ER by virtue of the first 27 amino acids, which 
contain a signal sequence (Sturley et al, 1994).  During ApoB translocation into the ER, pause 
transfer sequences are present throughout the protein to help with lipid loading (see section 1.5).  
In addition, the N-terminal 1000 amino acids interact with the MTP complex as they form a lipid 
binding pocket (Dashti et al, 2002).  
The ApoB domain structure is organized in a βα1-β1-α2-β2-α3 fashion (Segrest et al, 
2001; Segrest et al, 1994).  The N-terminus is termed βα1, as it is predicted to form a β-barrel 
followed by an α-helical region based upon homology to lipovitellin, an egg yolk lipoprotein 
(Mann et al, 1999; Segrest et al, 2001; Segrest et al, 1994).  ApoB has two additional, large β-
sheet domains at amino acids 827-2001 and 2571-4032.  There are also two smaller α-helical 
domains  containing amino acids 2045-2587 and 4017-4515 (Hussain et al, 2003; Segrest et al, 
2001; Segrest et al, 1994).  ApoB also contains 2 lipid associating domains, that span amino 
acids 1701-3101 and 4101-4536 (Segrest et al, 2001; Yang et al, 1989a; Yang et al, 1989b).  The 
LDL receptor binding region resides between amino acids 3345-3381.  Specifically, it was 
determined that once ApoB binds to the LDL receptor, a region between amino acids 2980 and 
3780 could no longer bind an antibody raise to this epitope.  Furthermore, it was shown that 
although ApoB67 (containing amino acids 1-3040) was unable to bind the LDL receptor, 
ApoB75 (containing amino acids 1-3387)retained this activity.  By combined with a sequence 
comparison to the better studied ApoE receptor and ApoB from seven species, the ApoB LDL  
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(A) The predicted ApoB domain structure contains a 27 amino acid signal sequence, which 
targets ApoB to the ER membrane and allows for translocation into the ER, and a β-barrel 
domain, which is directly followed by α-helix, β-sheet, α-helix motifs, and is interspersed by 2 
lipid association domains.  The naturally occurring isoforms, ApoB100 and ApoB48, and the 
disease causing truncation, ApoB29, are depicted using vertical blue lines.  The LDL receptor 
binding region is found in the β2 domain and is indicated with a horizontal green line.  The 16 
glycosylated asparagine residues in ApoB are indicated with triangles.  Of the 25 cysteine 
residues, only 16 participate in disulfide bond formation (red circles) while the remaining 9 are 
free sulfhydryls (open circles).  
(B) Computer simulated model of proposed ApoB structure (left) alone and (right) in 
lipoprotein.  Reprinted from Johs et al. 2006 with permission. 
Figure 2. Proposed Structural Domains and Modifications of ApoB. 
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(C) Artistic representation of lipoprotein particle.  The apolipoprotein wraps around the 
circumference of the lipoprotein which consists of phospholipids, free cholesterol, triglycerides, 
and cholesteryl ester.  Reprinted from (Feingold & Grunfeld, 2000)with permission.   
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receptor binding region was established (Boren et al, 1998; De Loof et al, 1986; Hussain et al, 
2003; Krul et al, 1992; Law & Scott, 1990; Milne et al, 1989; Weisgraber, 1994; Welty et al, 
1995; Yang et al, 1989a).  In addition, it is thought that the N and C termini interact with one 
another once ApoB is completely synthesized to provide structural rigidity to the spherical 
lipoprotein particle (Figure 2B and C) (Johs et al, 2006).   
As described earlier, ApoB is modified at several steps in the secretory pathway during 
lipoprotein particle maturation.  The two lipid associating domains allow for the conjugation of 
lipids onto ApoB by the MTP complex, facilitating ApoB’s incorporation into a pre-vLDL only 
when cholesterol and other neutral lipids are abundant.  In this way, ApoB is continuously being 
synthesized but is only able to deliver nutrients when available (see section 1.5).  Additionally, 
ApoB contains 25 cysteine resides but only 16 of these residues are used, to form 8 disulfide 
bonds (Fisher & Ginsberg, 2002; Harazono et al, 2005).  The formation of these bonds help 
assemble the final structure of the protein and consequently the lipoprotein particle as each 
domain can fold co-translationally as disulfide bonds are formed.  Furthermore, as with any 
secretory protein, ApoB can be glycosylated by the oligosaccharyltransferase in the ER.  ApoB 
has 19 potential sites for glycosylation, which are designated by an asparagine-X-
serine/threonine (where X can be any amino acid except proline), but only 16 are used (Bause & 
Hettkamp, 1979; Harazono et al, 2005).  In total, these secondary modifications help position and 
stabilize ApoB in the lipoprotein particle during synthesis and while circulating in the blood.  
Each modification  is carefully orchestrated to ensure proper synthesis, folding, and 
incorporation into lipoprotein particles.  For example, if cysteine 4326 is mutated then, ApoB 
fails to become incorporated into a lipoprotein (Callow & Rubin, 1995). Furthermore, if the 
cysteines involved in forming disulfide bonds 2 and 4 (amino acids 51, 70, 218, and 234) are 
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substituted, then ApoB secretion is reduced to 3% of wildtype levels and is unable to adopt its 
proper conformation a lipoprotein (Huang & Shelness, 1997).  Furthermore, if the 12 cysteines 
located in the N-terminus are mutated, then ApoB similarly fails to form a lipoprotein and the 
protein is degraded by the proteasome (Tran et al, 1998). 
As discussed in Section 1.1.3, studies have focused on modulating ApoB levels directly, 
namely by antisense oligonucleotides, as a way to directly regulate cholesterol levels (Ricotta & 
Frishman, 2012; Thomas & Ginsberg, 2010; Wong & Goldberg, 2014).  The first proof-of-
principle study underlying the clinical approach of targeting the ApoB message was conducted 
by Zimmerman and colleagues, who used an siRNA against ApoB.  The authors observed a 
reduction in ApoB levels as well as a reduction in circulating LDL and serum cholesterol levels 
in cytomogolous monkeys.  However, non-ApoB containing lipoprotein particles (i.e. HDLs) 
remained unaffected, which supports the idea that altering ApoB levels can specifically regulate 
cholesterol delivery (Zimmermann et al, 2006).  This and other studies ultimately led to the 
development of Mipomersen, as discussed above. 
1.4  ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION 
Nearly one third of all newly synthesized proteins enter the secretory pathway (Ghaemmaghami 
et al, 2003).  Once these proteins enter the ER, they properly fold, establish intradomain 
interactions, and assemble with additional protein partners or subunits (if necessary).  If secreted 
proteins do not achieve their proper conformations, they risk damaging the cell, which may 
manifest as human disease (Guerriero & Brodsky, 2012).  Therefore, the cell must have a way to 
monitor and remove such proteins.  One way to eliminate aberrant proteins in the secretory 
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pathway is through ER associated degradation (ERAD).  ERAD is a quality control pathway that 
monitors and selectively degrades misfolded or misassembled secretory proteins.   
ERAD is generally divided into four steps: substrate recognition, ubiquitination, 
retrotranslocation, and degradation (Guerriero & Brodsky, 2012; Preston & Brodsky, 2017; 
Stevenson et al, 2016).  Substrate recognition monitors misfolded proteins which result from an 
amino acid change in the cytoplasmic, membranous, or luminal region of the protein, or from a 
protein trapped in an incorrect folding intermediate state as a result of cellular stress (Brodsky, 
2007).  Nascent proteins entering the ER are monitored by molecular chaperones, which prevent 
off pathway folding intermediates from occurring, preventing aggregation, and helping to 
maintain the protein in a productive folding pathway (Balchin et al, 2016; Dobson, 2003).  
Misfolded proteins commonly expose stretches of hydrophobic amino acids.  Molecular 
chaperones bind these amino acid stretches and prevent hydrophobic regions from interacting 
and potentially aggregating in the hydrophilic environment of the ER lumen (Dobson, 2003).   
Once a misfolded protein is irreversibly misfolded, it is tagged with a polyubiquitin 
motif, which constitutes the second step of the ERAD pathway.  Ubiquitin is a 76 amino acid 
protein appended to protein substrates and can trigger different events including degradation, 
localization, and chromatin remodeling (Acconcia et al, 2009; Preston & Brodsky, 2017; 
Turinetto & Giachino, 2015).  Ubiquitin is most commonly added to the side chain of lysine in 
the protein substrate or can be appended at the N-terminus.  Ubiquitin itself contains 7 lysine 
residues, in addition to the N-terminus, which can be further modified to form linear or branched 
ubiquitin chains (Komander & Rape, 2012).  Polyubiquitin chains built on lysine-48 of the 
ubiquitin moiety commonly act as signals for degradation of the modified protein substrate by 
the 26S proteasome (Chau et al, 1989; Komander & Rape, 2012).   
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Ubiquitin is added to a protein through an enzymatic cascade.  First, an E1 activating 
enzyme activates the ubiquitin molecule through ATP hydrolysis to create a thiol-ester bond to 
the C-terminus of ubiquitin (Hershko et al, 1983; Pickart, 2001).  The activated ubiquitin is then 
conjugated to an E2 conjugating enzyme which further defines target protein specificity.  Finally, 
the ubiquitin is transferred to an E3 ubiquitin ligase, which in turn attaches ubiquitin onto the 
protein substrate (Komander & Rape, 2012; Preston & Brodsky, 2017).  Ubiquitin chains can 
also be extended with the help of a class of factors termed E4 ubiquitin chain extension enzymes 
(Koegl et al, 1999).  This cascade is opposed by the action of deubiquitinating enzymes (DUBs) 
that remove ubiquitin molecules from growing chains or at the proteasome immediately prior to 
degradation (Stevenson et al, 2016).  DUBs have been suggested to play a role in substrate 
discrimination and the DUB may specifically amplify the difference between a folded protein 
and an unfolded one through ubiquitin chain amplification (Zhang et al, 2013).  Ultimately, by 
continually adding and removing ubiquitin molecules, the conformation of a protein is monitored 
until at least 4 ubiquitin moieties remain, which signals protein degradation (Thrower et al, 
2000). 
Substrate polyubiquitin leads to retrotranslocation, the third step of ERAD.  
Retrotranslocation of proteins involves removal of the protein from the ER lumen or membrane 
into the cytoplasm.    To extract the protein, mechanical force must be used to pull the protein 
out of the ER by Cdc48 in yeast or p97 in mammals (Rabinovich et al, 2002; Ye et al, 2001).  
Cdc48p is a AAA+ ATPase that translates ATP hydrolysis into mechanical force to 
retrotranslocate proteins into the cytoplasm.  This protein forms a complex with two cofactors, 
Npl4 and Ufd1, which help bind ubiquitinated proteins and recruit Cdc48 at the ER membrane 
(Ye et al, 2001).  A mechanism for the retrotranslocation of proteins was recently put forth based 
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on a novel reconstituted system (Bodnar & Rapoport, 2017).  To retrotranslocate proteins, Npl4 
and Ufd1 first bind lysine-48 ubiquitinated substrates.  As a result, the substrate is locally 
denatured, which allows for the extension of a flexible loop of the protein into the Cdc48 cavity.  
Substrate binding can also stimulate ATPase hydrolysis, which further helps denature the protein 
as it is translocated through the central cavity.  Following hydrolysis, there is a conformational 
change which places the protein in close contact with a Cdc48-associated DUB, Otu1.  Otu1 can 
remove ubiquitin molecules until association with Npl4 and Ufd1 is lost and the protein is fully 
translocated and released from Cdc48.  Interestingly, not all ubiquitin moieties need to be 
removed from protein substrates during translocation through the Cdc48 pore.   
After the ubiquitinated protein is retrotranslocated from the ER, possibly through an 
integral membrane protein in the ER known as Hrd1, degradation is accomplished by the 26S 
proteasome (Schoebel et al, 2017).  This complex protease consists of a 20S core particle and a 
19S regulatory particle or “cap” (Budenholzer et al, 2017).  The 20S core particle contains 4 
stacked heptameric rings which facilitate protein degradation.  Facing the central cavity of the 
core particle are the residues responsible for the trypsin-like, chymotrypsin-like, and 
acidic/caspase-like protease activities used to hydrolyze proteins (Budenholzer et al, 2017; 
Kunjappu & Hochstrasser, 2014).  After recognition by ubiquitin receptors in the cap, the AAA 
ATPase in this particle drives proteins into the 20S core.  Moreover, through their N-terminal 
tails, the 19S cap can open the 20S core particle to facilitate protein entry into the central cavity 
of the 20S particle (Smith et al, 2007).  As noted above, there are also DUBs associated with the 
cap to remove the polyubiquitin chain and help denature the protein (Bashore et al, 2015; 
Elsasser et al, 2002; Shi et al, 2016).  In this manner, the 26S proteasome efficiently degrades 
only polyubiquintinated proteins.   
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1.5 APOLIPOPROTEIN B IS REGULATED BY ENDOPLASMIC RETICULUM 
ASSOCIATED DEGRADATION 
ApoB is a unique ERAD substrate as its levels are cotranslationally regulated by ERAD (Benoist 
& Grand-Perret, 1997; Liao et al, 1998; Mitchell et al, 1998).  This means that the level of ApoB 
turnover by ERAD is determined during synthesis by the amount of lipids present in the cell but 
not necessarily by the presence of misfolded ApoB.  This decision making process begins as 
ApoB is continuously translocated into the ER through a proteinaceous channel composed of the 
Sec61 complex (Mitchell et al, 1998; Robson & Collinson, 2006), which poises ApoB for a 
quick transition from degradation by ERAD to incorporation into pre-vLDLs (Figure 3A).  To 
form the pre-vLDL, the MTP complex transfers cholesterol, cholesterol esters, triacylglycerols, 
and phospholipids to ApoB via its lipid associating domains (Hussain et al, 1997; Hussain et al, 
2003).  As noted above, this process is further facilitated by pause transfer sequences and β-
sheets in ApoB (Chuck & Lingappa, 1992; Kivlen et al, 1997; Yamaguchi et al, 2006) (see also 
section 1.3.2).  These features slow translocation, which confers additional time for lipids to 
become attached to ApoB.  Once fully lipidated, translated, and translocated into the ER, ApoB 
enters the secretory pathway to become a mature lipoprotein particle (see section 1.2.2).   
When cholesterol is not adequately supplied by the diet and therefore the presence of 
ApoB and vLDLs is not required (Figure 3B).  In this case, cells synthesize their own supply of 
cholesterol.    Therefore, ApoB translocation slows,  and the ribosome can slightly detach from 
the ER, through an unknown mechanism (Dixon et al, 1991).  As ApoB translation still occurs, 
large loops of ApoB are exposed to cytoplasmic factors, including molecular chaperones and the 
ubiquitination machinery (Fisher et al, 1997; Pariyarath et al, 2001; Yeung et al, 1996).  
However, these events can also occur if MTP complex function is compromised or if ApoB  
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(A) When lipids are in excess, ApoB is required for the synthesis of a pre-vLDL. (1) ApoB is 
cotranslationally translocated into the ER where the MTP complex attaches lipids (purple 
diamonds) to ApoB. (2) This results in a pre-vLDL particle that contains ApoB. (3) ApoB exits 
the ER in a non-canonical COPII coated vesicle. (4) The pre-vLDL can undergo further 
maturation in the Golgi apparatus.  (5) If the particle fully matures, it will be secreted and enter 
Figure 3. ApoB is Metabolically Regulated by ERAD. 
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the bloodstream to deliver cholesterol.  If the particle does not fully mature, it can also be sent to 
the lysosome to be degraded by post ER presecretory proteolysis.  
(B) If lipids are limiting or MTP function is blunted, then ApoB does not become lipidated.  
Translocation slows which exposes large cytoplasmic loops of ApoB.  These loops can be acted 
upon by chaperones and the ubiquitination machinery.  Once the loops are ubiquitinated, ApoB 
is retrotranslocated and targeted to the proteasome for degradation.   
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cannot be properly lipid loaded.  These chaperones that interact with ApoB include the ER 
luminal lectin, Calnexin, and PDI family members along with cytosolic Hsp70, Hsp90, and 
Hsp110, which either help to promote (Hsp70, Hsp90, PDIs) or inhibit (Hsp110) ApoB 
degradation (Fisher et al, 1997; Grubb et al, 2012; Gusarova et al, 2001; Hrizo et al, 2007; Liao 
et al, 1998).   Eventually, ApoB is ubiquitinated on the exposed cytoplasmic loops by the E3 
ubiquitin ligase Hrd1 (in yeast) or gp78 (in humans) (Jiang & Song, 2014; Liang et al, 2003; 
Rubenstein et al, 2012).  Finally, ApoB is retrotranslocated by the p97 ATPase and degraded by 
the 26S proteasome (Cardozo et al, 2002; Fisher et al, 2008).  As a result of these events, ApoB 
fails to enter the secretory pathway and cannot be secreted.    
1.6 APOLIPOPROTEIN B DEGRADATION BY POST ER PRESECRETORY 
PROTEOLYSIS 
ApoB is also subject to an alternate degradation pathway, post ER presecretory proteolysis 
(PERPP).  Following translation and translocation, ApoB folding and pre-vLDL maturation may 
also fail in the late secretory pathway or ApoB can be oxidized by polyunsaturated fatty acids 
after transport from the ER.  These aberrant and/or modified ApoB species are degraded by 
PERPP, which unlike ERAD, degrades ApoB in the presence of normal levels of triglycerides.  
PERPP is a specialized form of autophagy that occurs in the Golgi during maturation of the 
vLDL particle (Brodsky & Fisher, 2008; Fisher et al, 2001; Ginsberg & Fisher, 2009; Pan et al, 
2004).  As noted in section 1.1.3, autophagy can degrade proteins, cellular aggregates, and 
damaged organelles by delivering these particles to the lysosome through a double membrane 
bound vesicle (Levine & Kroemer, 2008; Yun et al, 2017).   
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1.6.1 N-3 Fatty Acid Induced Degradation  
PERPP occurs when an immature vLDL cannot undergo complete maturation but has exited the 
ER.  If a pre-vLDL exhibits a  defect or oxidative damage and cannot mature, it may aggregate in 
the Golgi (Fisher et al, 2001; Pan et al, 2004).  Therefore, it must be degraded, but the resulting 
aggregates are likely too large and complex to be targeted for proteasomal degradation.  In this 
case, the particles are sequestered and delivered to the lysosome for degradation.  Consistent 
with this idea, when the proteasome is inhibited (and the levels of polyubiquitinated and 
aggregation-prone ApoB rise), increased amounts of ApoB are found in the lysosome (Ohsaki et 
al, 2006).  PERPP is specifically stimulated by N-3 fatty acids, such as eicosapentaenoic and 
docosahexaenoic acid, which cause oxidative damage and increased intracellular degradation of 
ApoB (Fisher et al, 2001; Pan et al, 2004; Wang et al, 1993).  Interestingly, a diet rich in these 
N-3 fatty acids correlates with lower triglyceride level (Djousse et al, 2003; Harris, 1989).  This 
may be a result of stimulating the PERPP of ApoB, which lowers circulating LDL particles.   
1.6.2 Insulin Induced Degradation 
ApoB degradation by PERPP can also be stimulated by an acute increase in insulin, which 
decreases vLDL and ApoB secretion (Biddinger et al, 2008; Chirieac et al, 2000; Sparks & 
Sparks, 1990; Taghibiglou et al, 2000).  This process is mediated through MAP kinase, TNFα, 
and PI3-kinase (Phung et al, 1997; Qin et al, 2007; Tsai et al, 2007).  Specifically, insulin 
activates the downstream PI3-kinase which leads to the production of PI3P, preventing ApoB 
from acquiring triglycerides and forming vLDL, (Au et al, 2004; Chirieac et al, 2006; Phung et 
al, 1997; Sparks & Sparks, 2008).  ApoB and vLDL secretion rise in insulin resistance and type 2 
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diabetes mellitus, suggesting that insulin resistance may be a consequence of  heightened ApoB 
secretion (Khavandi et al, 2017).   
 
1.7 CONCLUSION 
In attempt to treat a multitude of diseases including multiple cancers, attempts to target 
chaperones and other pathway regulators have been attempted.  One approach is the use of small 
molecule inhibitors, protein aptamers, and antibodies against different domains of Hsp70.  For 
example, classes of compounds including dihydropyrimides, (e.g. MAL3-101 and SW02) and 
flavonoids (e.g. epigallacatchin and myricetin) target the nucleotide binding domain of Hsp70 
(Chatterjee & Burns, 2017).  Protein aptamers target the substrate binding domain, and an 
antibody therapy targets an epitope of Hsp70 (Chatterjee & Burns, 2017).  The flavonoid, 
epigallocetchin, and one specific antibody against Hsp70 are undergoing clinical trials (Chang et 
al, 2011; Goloudina et al, 2012; Powers et al, 2010; Rerole et al, 2011).  Similarly, inhibitors of 
Hsp90 have been identified and are undergoing clinical trials for treatment of cancers.  These 
compounds appear to inhibit the ATPase activity and/or tightly bind to Hsp90 to prevent its 
function (Renouf et al, 2016; Wagner et al, 2016; Yong et al, 2016).  Interestingly, a new class of 
compounds which enhances Hsp70 activity has also been recently identified (Wisen et al, 2010).  
One of the compounds, 115-7c, appears to bind at the hsp70-hsp40 interface, to which may 
regulate interaction (Wisen et al, 2010).  
Both the ERAD and PERPP pathways for ApoB degradation are regulated by  various 
factors, including lipids, post-translational modifications, molecular chaperones, and hormones.  
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Since ApoB levels directly correlate with circulating LDLs, vLDLs, serum cholesterol, and 
triacylglycerol, I hypothesize that factors that regulate ApoB could also be therapeutic targets to 
regulate cholesterol levels.  Already, a small molecule inhibitor of Hsp90, geldanamycin, has 
been shown to nearly completely prevent ApoB degradation in an in vitro 
transcription/translation assay (Gusarova et al, 2001).  Similarly, inhibiting the proteasome via 
ALLN prevented ApoB degradation while overexpression of Hsp70, which binds ApoB, 
promoted ApoB degradation in mammalian cells (Fisher et al, 1997; Zhou et al, 1995).  Thus, 
these and other factors may represent new and alternative approaches to treat CAD.  In this 
thesis, I describe a new ApoB Saccharomyces cerevisiae expression system that I developed and 
then used to identify additional regulators of ApoB degradation.  Specifically, I investigated the 
role of lipid droplets as a site of short term storage prior to degradation.  I subsequently 
investigated a variety of chaperones that have potential “holdase,” “foldase,” and “disaggregase” 
activity towards ApoB, including the Tcp-1 ring complex, the small heat shock proteins, and 
Hsp104.   
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2.0  HSP104 FACILITATES APOLIPOPROTEIN B DEGRADATION 
ApoB is a large, hydrophobic secretory protein that translocates into the ER.  ApoB levels are 
controlled via its degradation.  If it is misfolded or not adequately lipidated, then it is degraded 
via the ERAD pathway.  During ERAD, ApoB translation slows, exposing cytoplasmic loops 
which become ubiquitinated signaling for retrotranslocation into the cytoplasm and degradation 
by the 26S proteasome (Cardozo et al, 2002; Dixon et al, 1991; Fisher et al, 2008; Fisher et al, 
1997; Pariyarath et al, 2001; Rubenstein et al, 2012; Yeung et al, 1996).  Once ApoB has been 
retrotranslocated, it has the potential to aggregate.  These aggregates are likely one of the triggers 
for degradation. 
 Previous work established that soluble, luminal ERAD substrates (mutant forms of 
carboxypeptidase Y, CPY*, and proalpha factor, ΔGpF) also have the potential to aggregate in 
the ER (Nishikawa et al, 2001).  Using yeast strains that lack two ER-localized Hsp40s, Scj1 and 
Jem1, the authors showed that in cooperation with the ER luminal Hsp70, Kar2, the Hsp40s 
helped to facilitate CPY* and ΔGpF degradation.  Moreover, impairment of Kar2 or Scj1 and 
Jem1 lead to aggregation of CPY* and ΔGpF as assessed via sucrose gradient fractionation.  The 
authors proposed that these factors help maintain protein solubility in the ER, since aggregation 
could prevent retrotranslocation and result in ER stress.  Interestingly, some ERAD substrates 
perpetually aggregate in the ER and cause diseases such as α-1-antitrypsin deficiency(Silverman 
et al, 2013).   
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To prevent ApoB aggregation during retrotranslocation, I hypothesize that cellular 
factors, such as lipid droplets or specific chaperones, interact with ApoB to maintain its 
solubility.  Lipid droplets are ER-associated organelles which store lipids for the cell to use 
during stressful times but have also been shown to interact with aggregation prone proteins 
before they are degraded (Cole et al, 2002; Farese & Walther, 2009).  Holdase chaperones 
physically interact with their substrate to help prevent protein aggregation.  These chaperones 
include ATP dependent factors, such as TRiC and Hsp104, and ATP independent factors, such as 
the small heat shock proteins.  TRiC is important for folding ~5% of all newly synthesized 
proteins, including actin and tubulin (Joachimiak et al, 2014).  Hsp104 is a AAA+ ATPase that 
cooperates with Hsp70 and Hsp40 to remove proteins from aggregates and help them refold 
(Shorter, 2017).  The small heat shock proteins are conserved chaperones that physically interact 
with their substrate by binding through their conserved α-crystallin domain (Burnie et al, 2006).  
Among these factors, only the small heat shock proteins have been shown to function during 
ERAD, and even in this case only one substrate was affected (Ahner et al, 2007).  With the 
exception of Hsp104, all of these factors are conserved from yeast to humans. In order to 
investigate if these factors affect ApoB degradation, I developed a new β-estradiol ApoB 
expression for use in the yeast Saccharomyces cerevisiae.  In this chapter, I discuss the 
development of the new expression system and then my investigation to determine if lipid 
droplets or the various holdase chaperones affect ApoB degradation.   
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2.1 MATERIALS AND METHODS 
2.1.1 Yeast strains, strain construction, plasmids, and growth conditions 
Unless otherwise noted, yeast strains were grown at 30°C using standard growth, media, and 
transformation conditions (Adams et al, 1998). Yeast strains utilized in this study are listed in 
Table 1.  
Yeast strains were made β-estradiol inducible by linearizing pACT1-GEV (Veatch et al, 
2009) (Allyson O’Donnell, Duquesne University) using EcoRV (New England Biolabs) 
according to the manufacturer’s specifications. Linearized plasmid was transformed into log 
phase yeast cells and integrated at leu2Δ0 using the standard lithium acetate protocol (Adams et 
al, 1998). Transformants were selected on YPD plates containing 0.1 mg/mL Nourseothricin 
(Werner Bioagents, Jena, Germany).  Positive transformants were restruck 3 times onto YPD 
plates supplemented with the antibiotic to ensure successful integration.  
To drive expression of ApoB29 in yeast from the GAL promoter, plasmid pSLW1-B29-
HA was used (Hrizo et al, 2007).  Plasmid pJJB20, which lacks the ApoB29 coding sequence, 
was used as a negative control vector for ApoB29 as was previously described (Hrizo et al, 
2007).  To constitutively express Hsp104, plasmid pRS315-Hsp104 plasmid was used (Preston et 
al. in review). To constitutively express Rvb2, pRS425-Rvb2 was used.  pRS425-Rvb2 was 
constructed by digesting pFL44-Rvb2 (Yury Chernov, Georgia Institute of Technology) and 
ligating the insert into pRS425 (Mumberg et al, 1995) using the BamHI and SalI sites. 
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Table 1. Yeast Strains Utilized. 
Strain Genotype Source 
W303 MAT α, ade2-1, can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1 
This lab 
LDY020 
 
MAT α, ade2-1, can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, ACT1-GEV-NatMX::leu2Δ0 
This study 
pdr5Δ MAT α, ade2-1 can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, pdr5::KANMX4, ACT1-GEV-
NatMX::leu2Δ0 
This lab 
LDY001 MAT α, ade2-1 can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, pdr5::KANMX4, 
This study 
BY4742 MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0 This lab 
LDY022 MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0 ACT1-GEV-
NatMX::leu2Δ0 
This study 
pep4Δpdr5Δ MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0, met15Δ0, 
pdr5::KANMX4, pep4::KANMX4 
This lab 
LDY027 MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0, met15Δ0, 
pdr5::KANMX4, pep4::KANMX4, ACT1-GEV-
NatMX::leu2Δ0  
This study 
MHY500 MAT a, his3-Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2 
Rubenstein et al., 
2012. 
hrd1Δ MAT a, his3- Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, hrd1::LEU2 
Rubenstein et al., 
2012. 
doa10Δ MAT a, his3- Δ200 leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, doa10::HIS3 
Rubenstein et al., 
2012. 
hrd1Δdoa10Δ MAT a, his3- Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, hrd1::LEU2, doa10::HIS3 
Rubenstein et al., 
2012. 
LDY043 MAT a, his3- Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, ACT1-GEV-NatMX::leu2Δ0 
This study 
LDY044 MAT a, his3- Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, hrd1::LEU2, ACT1-GEV-
NatMX::leu2Δ0 
This study 
LDY045 MAT a, his3- Δ200 leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, doa10::HIS3, ACT1-GEV-
NatMX::leu2Δ0 
This study 
LDY046 MAT a, his3- Δ200, leu2-3,112, ura3-52, lys2-801,  
trp1-1, gal2, hrd1::LEU2, doa10::HIS3, ACT1-GEV-
NatMX::leu2Δ0 
This study 
png1Δ MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0, 
png1::KANMX4 
This lab 
LDY026 MAT α, his3Δ1, leu2Δ0, ura3Δ0, lys2Δ0, 
png1::KanMX4, ACT1-GEV-NatMX::leu2Δ0 
 
This study 
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H1246  
Lipid Droplet 
Deficient 
MAT a, ade2-1, can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, are1::HIS3, are2::LEU2, 
dga1::KANMX4, lro1::TRP1ADE2 
Sandager et al. 
2002. 
Tgl3-GFP MAT a, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0, 
TGL3::GFP-HIS3MX6 
Athenstaedt and 
Daum, 2003. 
LDY003 MAT a, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0, 
TGL3::GFP-HIS3MX6, ACT1-GEV-NatMX::leu2Δ0 
This study 
SEY6211 MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL 
Haslbeck et al., 
2004. 
hsp26Δ MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL, hsp26::HIS 
Haslbeck et al., 
2004. 
hsp42Δ MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL. hsp42::LEU 
Haslbeck et al., 
2004. 
hsp26Δhsp42Δ MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL, hsp26::HIS, hsp42::LEU 
Haslbeck et al., 
2004. 
LDY002 
 
MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL, ACT1-GEV-NatMX::leu2Δ0 
This study 
LDY016 
 
MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL, hsp26::HIS, ACT1-GEV-
NatMX::leu2Δ0 
This study 
LDY017 
 
MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL. hsp42::LEU, ACT1-GEV-
NatMX::leu2Δ0 
This study 
LDY018 
 
MAT a, ura3-52, leu2-3, 112, his-d200, trp1-d901, 
ade2-101, suc2-d9 GAL, hsp26::HIS, hsp42::LEU, 
ACT1-GEV-NatMX::leu2Δ0 
This study 
DUY558 MAT a, leu2-3,-112, ura3-52, trp1-7 tcp::LEU2 
(YCpMS38; TCP1::TRP,) 
Ursic and 
Culbertson, 1991. 
LDY028 MAT a, leu2-3,-112, ura3-52, trp1-7 tcp::LEU2 
(YCpMS38; TCP1::TRP1), ACT1-GEV-
NatMX::leu2Δ0 
This study 
DUY326 MAT a, leu2-3,-112, ura3-52,trp1-7 tcp::LEU2 
(YCpMS38; tcp1-2::TRP1) 
Ursic and 
Culbertson, 1991. 
LDY029 MAT a, leu2-3,-112, ura3-52,trp1-7 tcp::LEU2 
(YCpMS38; tcp1-2::TRP1), ACT1-GEV-
NatMX::leu2Δ0 
This study 
hsp104Δ MAT α, ade2-1, can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, hsp104::KANMX4 
Preston et al, in 
review 
LDY021 
 
MAT α, ade2-1, can1-100, his3-11,15, leu2-3,112, 
trp1-1, ura3-1, hsp104::KANMX4, ACT1-GEV-
NatMX::leu2Δ0 
This study 
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  To monitor protein production, yeast were grown overnight in synthetic minimal media 
lacking uracil supplemented with 2% glucose at 30°C.  Cultures were diluted in the same media 
and allowed to grow to log phase (OD600 = 0.4-0.6).  A total of 16 OD600s of cells were 
harvested, washed once in water, and resuspended in synthetic minimal media supplemented 
either with either 2% galactose (to induce expression) or 2% glucose supplemented with 300 nM 
β-estradiol (to induce ApoB29 expression in the GEV strain; see section 2.2.1) and were 
incubated at 30°C.  At the indicated timepoints, equal amounts of cells were harvested.  Proteins 
were precipitated using tricholoroacetic acid (TCA) as previously described (Zhang et al, 2001) 
and immediately resolved by SDS-PAGE, followed by western blotting.  Immunoblots were 
incubated with anti-HA (for ApoB) and anti-G6PD (as a loading control) antibodies as described 
below.   
To cure strains of prions, wildtype and hsp104Δ yeast were grown on YPD plates 
supplemented with 3 mM guanidine hydrochloride and grown at 30°C (Jung et al, 2002).  
Individual yeast colonies were streak plated twice more onto YPD plates supplemented with 3 
mM guanidine hydrochloride, for a total of 3 times.   
 
2.1.2 Antibodies and Quantitative Western Blotting 
Antibodies used in this study are as follows: horseradish peroxidase (HRP) conjugated rat anti-
HA (Roche Applied Science, 3F10) used at 1:5000 dilution; rabbit anti-glucose 6 phosphate 
dehydrogenase (G6PD) (Sigma) used at 1:5000 dilution; HRP conjugated donkey anti-rabbit (GE 
Healthcare) used at 1:5000 dilution; rabbit anti-Protein Disulfide Isomerase (PDI) (Dr. Vlad 
Denic, Harvard University) used at 1:5000 dilution; rabbit anti-Kar2 (Brodsky & Schekman, 
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1993) used at 1:5000 dilution; rabbit anti-Anp1 (Hugh Pelham, MRC Laboratories of Molecular 
Biology) used at 1:4000 dilution; rabbit anti-Sec61 (raised again peptide: LVPGFSDLM and 
isolated by Cocalico Biologicals, Stevens, PA) used at 1:1000 dilution; mouse anti-Pma1 
(Abcam) used at 1:1000 dilution; mouse monoclonal anti-GFP (Roche) used at 1:1000 dilution; 
HRP conjugated monoclonal anti-mouse (Cell Signaling Technology) used at 1:5000 dilution; 
mouse monoclonal anti-Vph1  (Abcam, 10D7A7B2) used at 1:5000 dilution; rabbit anti-Hsp104 
(Dr. John Glover, University of Toronto) used at 1:1000 dilution; rabbit anti-Sse1 (Hrizo et al, 
2007) used at 1:5000 dilution; rabbit anti-Ssa1 (Hrizo et al, 2007) used at 1:5000 dilution;  rabbit 
anti-L5 (Dr. John L. Woolford, Carnegie Mellon University) used at 1:1000 dilution.   
Following SDS-PAGE, proteins were transferred to nitrocellulose overnight and 
incubated with the appropriate antibodies.  Proteins were visualized using the SuperSignal West 
Pico Chemiluminescent substrate kit (ThermoFisher Scientific) or SuperSignal West Femto 
Maximum Sensitivity chemiluminescent substrate kit (ThermoFisher Scientific).  Images were 
obtained and quantified using either a Kodak 440CF Image station and the associated Kodak 1D 
software (Eastman Kodak, Rochester, NY) or BioRAD Universal Hood II Imager and ImageJ 
software version 1.48v (National Institutes of Health).  Unless otherwise stated, all quantitation 
shown describes both ApoB molecular weight species. All quantitation is done for each species 
individually and both bands together.  Half-lives were calculated using Sigmaplot. 
 
2.1.3 Protein Degradation Assays 
ApoB degradation assays using the galactose inducible system with plasmid pSLW1-B29-HA 
were performed at 30°C as previously described (Grubb et al, 2012; Hrizo et al, 2007).  To 
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determine the rate of ApoB29 degradation using the β-estradiol inducible system, yeast 
harboring the pACT1-GEV insert and transformed with pSLW1-B29 were grown overnight in 
synthetic minimal media lacking uracil but supplemented with 2% glucose at 30°C.  Overnight 
cultures were diluted and grown to logarithmic phase (OD600 = 0.4-0.6) for at least 2 hours. 
ApoB29 protein expression was then induced using 300 nM β-estradiol for 2 hours at 30°C.  
Equal amounts of yeast (10 OD600 equivalents) were harvested and resuspended to 5 OD600/mL 
in synthetic minimal media lacking uracil supplemented with 2% glucose and 300 nM β-
estradiol.  Cycloheximide chase assays were conducted at 30°C or 37°C, as indicated, similar to 
previously published protocols (Grubb et al, 2012; Hrizo et al, 2007).  Protein synthesis was 
stopped using 50 µg/mL cycloheximide, and at the indicated timepoints, 2 OD600 units of cells 
were harvested.  Proteins were precipitated as previously described (Zhang et al, 2001) and 
samples were immediately resolved by SDS-PAGE followed by western blotting.  Immunoblots 
were incubated with anti-HA and anti-G6PD antibodies as described above.  
 
2.1.4 Isolation of Yeast Microsomes 
A total of 2 L of yeast containing plasmid pSLW1-B29-HA were grown to log phase (OD600 = 
0.4-0.6) in synthetic minimal media lacking uracil supplemented with 2% glucose.  ApoB protein 
expression was induced with 300 nM β-estradiol and cells were grown at 30°C for 2 hours.  The 
yeast cells were then harvested and resuspended in 1/40th of the original volume using minimal 
media lacking uracil supplemented with 2% glucose and 300 nM β-estradiol and then cells were 
incubated at 30°C or 37°C for 1 hour, as indicated, in a shaking water bath.  The cells were next 
harvested, washed in water, and frozen at -80°C.   
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Medium scale microsomes were prepared as previously described (Nakatsukasa et al, 
2008).  In brief, the cells were lysed in 20 mM HEPES, pH 7.4, 50 mM KOAC, 2 mM EDTA, 
0.1 M sorbitol, 1 mM DTT plus protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 0.5 µg/mL 
pepstatin A) by glass bead agitation on a Vortex mixer 10 times in 30 second intervals with 
incubations on ice in between each step.   After the lysate was removed, the beads were rinsed 
twice with buffer, which was combined with the lysate, and the mixture was layered onto a 
sucrose cushion (20 mM HEPES, pH 7.4, 50 mM KOAc, 1.0 M sucrose, 1 mM DTT), and 
centrifuged at 6,500 rpm for 10 minutes at 4°C in an HB-6 rotor (Sorvall).  The supernatant was 
collected and centrifuged again at 9,500 rpm for 10 minutes at 4°C in an HB-6 rotor.  The pellets 
were washed in Buffer 88 (20 mM HEPES, pH 6.8, 150 mM KOAc, 250 mM sorbitol, 5 mM 
MgOAc), recentrifuged as above, and the final pellet was resuspended in Buffer 88 to a final 
concentration of 10 mg/mL (OD280 = 40 in 2% SDS).  Aliquots were flash frozen in liquid 
nitrogen and stored at -80°C.   
 
2.1.5 Biochemical Methods 
To visualize the EndoH sensitive pool of ApoB, yeast transformed with pSLW1-B29-HA were 
grown to log phase (OD600 = 0.4-0.6) at 30°C and ApoB protein expression was induced using 
300 nM β-estradiol for 2 hours at 30°C.  Equal amounts of protein were harvested, precipitated, 
and resuspended in sample buffer as previously described (Zhang et al, 2001).  Samples were 
treated in the presence or absence of Endoglycosidase H (Roche) for 2 hours at 37°C according 
to the manufacturer’s specifications. Proteins were subsequently resolved by SDS-PAGE and 
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immunoblot analysis was conducted with anti-HA, anti-G6PD, and anti-PDI antibodies, as 
described above. 
To perform limited proteolysis studies, 200 mg of microsomes, prepared as described 
above, were combined with Buffer 88 on ice.  The “0 minute” timepoint was removed, mixed 
with final concentration of 30% TCA, and stored on ice.  The remaining reaction was incubated 
with 0.04 mg/mL of Proteinase K (Sigma) on ice and samples were taken at the indicated 
timepoints, combined with a final concentration of 30% TCA, and stored on ice.  All samples 
were then centrifuged at 13,000 rpm, for 10 minutes at 4°C in a microcentrifuge.  The pellets 
were washed with acetone, air dried, and resuspended in TCA sample buffer (80 mM Tris, pH 8, 
8 mM EDTA, 120 mM DTT, 3.5% SDS, 0.29% glycerol, 0.08% Tris base, 0.01% bromophenol 
blue).  The final samples were heated to 37°C for 20 minutes and resolved by SDS-PAGE 
followed by western blotting.  Immunoblots were incubated with anti-HA, anti-Kar2, and anti-
Sec61 antibodies, as described above. 
 Carbonate extraction was conducted on yeast expressing ApoB essentially as described 
(Buck et al, 2016).  In brief, yeast cells containing pSLW1-B29-HA were grown at 30°C until 
log phase (OD600 = 0.4-0.6) in synthetic minimal media lacking uracil and supplemented with 
2% glucose.  ApoB protein expression then was induced using 300 nM β-estradiol for 2 hours at 
30°C.  The yeast were harvested and resuspended in IP Buffer I (20 mM HEPES, pH 7.4, 50 mM 
KOAc, 2 mM EDTA, 0.1 M sorbitol) plus protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 
0.5 µg/mL pepstatin A) and lysed using glass bead agitation on a Vortex mixer 4 times in 1 
minute intervals with incubations on ice in between each step.  Unbroken cells were removed by 
centrifugation at 2,500 rpm for 3 minutes at 4°C in a microcentrifuge.  Next, the supernatant was 
removed and centrifuged to isolate crude membranes at 14,000 rpm for 20 minutes at 4°C in a 
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microcentrifuge.  Membranes were resuspended in IP Buffer I plus protease inhibitors and 
recentrifuged as above.  Finally, the resuspended membranes were incubated with either 0.1 M 
Na2CO3 or Buffer 88, both which were supplemented with protease inhibitors, and incubated on 
ice for 30 min.  The samples were centrifuged at 50,000g for 1 hour at 4°C in a SW 55 Ti rotor 
(Beckman) and the supernatant and pellet samples were saved.  The pellets were resuspended in 
0.1 M Na2CO3 or Buffer 88, as appropriate, and centrifuged at 60,000g for 10 minutes at 4°C in 
a SW 55 Ti rotor.  The final pellets were resuspended in TCA sample buffer using a mechanical 
pestle.  The supernatant samples were mixed with a final concentration of 5% TCA and 
incubated on ice for 15 minutes.  These samples were centrifuged at 14,000 rpm for 10 minutes 
at 4°C in a microcentrifuge and pellets were resuspended in TCA sample buffer using a 
mechanical pestle.  Supernatant and pellet samples were incubated at 37°C for 20 minutes 
followed by SDS-PAGE and western blotting.  Immunoblots were incubated with anti-HA, anti-
Sec61, and anti-PDI antibodies, as described above.   
 
2.1.6 Sucrose Gradient Sedimentation 
The intracellular localization of ApoB by equilibrium density sucrose gradient analysis was 
examined essentially as described (O'Donnell et al, 2017). In brief, yeast containing pSLW1-
B29-HA were grown overnight in synthetic minimal media lacking uracil and supplemented with 
2% glucose at 30°C.  Overnight cultures were diluted and grown to logarithmic phase (OD600 = 
0.4-0.6) for at least 2 hours. Either 80 or 150 OD600 equivalents of cells were harvested at 3000 
rpm for 3 minutes at room temperature in a clinical centrifuge.  The yeast were washed in water 
and resuspended in twice the OD600 equivalent volume of YP supplemented with 2% galactose.  
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Expression of the ApoB29 protein was induced for 4 hours at 30°C.  Next, the yeast expressing 
ApoB were resuspended in 400 µL of 10% sucrose and flash frozen in liquid nitrogen in a 
dropwise fashion.  The frozen yeast pellets were ground with a mortar and pestle(15 strokes, 6 
times with liquid nitrogen being added in between), and the samples were thawed and 
centrifuged for 2 minutes at 2000 rpm at 4°C.  Five percent of the supernatant was saved for the 
input fraction and the remaining lysate was loaded onto the gradient (see below). 
In parallel, a 70% sucrose stock solution (70% sucrose, 10 mM Tris, pH 7.6, 2 mM 
MgCl2, 1 mM DTT) supplemented with protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 
0.5 µg/mL pepstatin A) was used to created sucrose dilutions of 10-60%.  Discontinuous sucrose 
gradients of either 20-70% sucrose or 10%, 35%, 50%, 70% sucrose were poured.  For the 20-
70% gradients, 2 mL of 70%, 60%, 50%, and 40% and 1.5 mL of 30% and 20% sucrose were 
layered.  For the 10%, 35%, 50%, 70% gradients, 1.5 mL of 10% and 70% and 4 mL of 35% and 
50% were layered as appropriate.   After the lysate, prepared as described above, was overlaid at 
the top of the gradients, the samples were centrifuged at 28,500 rpm at 4°C for 18.5 hours in a 
SW-41 rotor.  Fractions (500 µL) were carefully removed from the top of the gradient.  A 20 µL 
aliquot of each fraction was then combined with 5µL 5X SDS sample buffer (0.325 M Tris, pH 
6.8, 10% SDS, 50% glycerol, 25 mg/mL bromophenol blue, 5% β-mercaptoethanol), incubated 
at room temperature for 10 minutes, and subjected to SDS-PAGE followed by western blotting.  
Immunoblots were incubated with anti-HA, anti-Anp1, anti-Sec61, anti-Pma1, and anti-GFP 
antibodies, as described above.   
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2.1.7 Lipid Droplet Isolation 
Lipid droplets were isolated essentially as described (Leber et al, 1994).  In brief, 2 L of yeast 
containing plasmid pSLW1-B29 were grown at 30°C to log phase (OD600 = 0.4-0.6) in synthetic 
minimal media lacking uracil and supplemented with 2% glucose.  ApoB protein expression was 
induced using 300 nM β-estradiol for 2 hours at 30°C and cells were harvested and stored at-
80°C.  The cell pellets were then resuspended in 100 mM Tris, pH 9.4, supplemented with 10 
mM DTT, and incubated at room temperature (~21°C) for 15 minutes.  The cells were again 
harvested in an HB-6 rotor at 5,000 rpm for 5 minutes at 4°C and resuspended in lyticase buffer 
(0.7 M sorbitol, 75% Yeast extract and Peptone, 0.5% glucose, 10 mM Tris, pH 7.4) 
supplemented with 5 mM DTT.  The cell walls were removed with 2 mL lyticase for 15 minutes 
at 30°C in a shaking water bath and the spheroplasted yeast were overlaid onto a sucrose cushion 
(0.8 M sucrose, 1.5% Ficoll 400, 20 mM HEPES, pH 7.4) and centrifuged in an HB-6 rotor at 
6,000 rpm for 10 minutes at 4°C. The pelleted spheroplasts were next resuspended in wash 
buffer (20 mM KPO4, pH 7.4, 1.2 M sorbitol) and recentrifuged as above.  The pellet was 
resuspended in breaking buffer (10 mM MES-Tris, pH 6.9, 12% Ficoll 400, 0.2 mM EDTA) plus 
protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 0.5 µg/mL pepstatin A) and cells were 
lysed with 15 slow strokes using a loose fit Dounce homogenizer on ice.  Next, the homogenate 
was diluted with 1 volume of breaking buffer plus protease inhibitors and centrifuged in an HB-6 
rotor at 5,500 rpm for 5 minutes at 4°C.  The supernatant was removed and then overlaid with an 
equal volume of breaking buffer plus protease inhibitors and centrifuged in a SW-28 swinging 
bucket rotor (Beckman) at 28,000 rpm for 1 hour at 4°C.  The floating layer was mixed with 1 
volume of breaking buffer plus protease inhibitors, and mixed using a loose fit Dounce 
homogenizer with 10 strokes on ice.  This sample was overlaid with an equal volume of 10 mM 
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MES-Tris, pH 6.9, 8% Ficoll 400, 0.2 mM EDTA plus protease inhibitors, and this mixture was 
again ultracentrifuged at 28,000 rpm for 1 hour at 4°C in SW-28 rotor.  The top floating layer 
was removed and gently combined with an equal volume of 10 mM MES-Tris, pH 6.9, 0.6 M 
sorbitol, 8% Ficoll 400, 0.2 mM EDTA plus protease inhibitors.  This sample was overlaid with 
an equal volume of 10 mM MES-Tris, pH 6.9, 0.25 M Sorbitol, 0.2 mM EDTA plus protease 
inhibitors and ultracentrifuged at 28,000 rpm for 30 minutes at 4°C in SW-28 rotor.  Highly 
enriched lipid droplets were isolated from the top of the gradient, mixed with a final 
concentration of 10% TCA, incubated on ice for 20 minutes, and centrifuged at 14,000 rpm for 
15 minutes at 4°C in a microcentrifuge.  The pelleted samples were washed with acetone, 
recentrifuged, and the pellets were allowed to air dry.  The final pellets were resuspended in 
TCA sample buffer using a mechanical pestle and were run on SDS polyacrylamide gels 
followed by western blotting.  Immunoblots were incubated with anti-HA, anti-GFP, anti-Vph1, 
and anti-Sec61 antibodies, as described above.   
 
2.1.8 Coimmunoprecipitation Assays 
Yeast containing pSLW1-B29-HA were grown at 30°C to log phase (OD600 = 0.4-0.6) in 
synthetic minimal media lacking uracil supplemented with 2% glucose. The ApoB protein was 
induced using 300 nM β-estradiol for 2 hours at 30°C and a total of 100 OD600 cells were 
harvested and stored at -80°C. Next, the thawed cells were resuspended in 1 mL lysis buffer (50 
mM Tris, pH 7.5, 150 mM NaCl, 0.1% NP-40) plus protease inhibitors (1 mM PSMF, 1 µg/mL 
leupeptin, 0.5 µg/mL pepstatin A)  and cOmplete EDTA-free protease inhibitor cocktail (Roche). 
The cells were then lysed using glass bead agitation on a Vortex mixer 6 times for 1 minute 
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intervals on ice in between each lysis step and the lysate was centrifuged at 5000 rpm for 2 
minutes at 4°C in a refrigerated microcentrifuge.  The supernatant was saved and recentrifuged at 
5000 rpm for 2 minutes at 4°C in a refrigerated microcentrifuge.  The final supernatant was then 
precleared using 30 µL of Protein G Fast Flow Sepharose (GE Healthcare) resuspended in 50 
mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA) for 45 minutes at 4°C.  Samples were 
centrifuged at 5000 rpm for 2 minutes at 4°C in a refrigerated microcentrifuge and the 
supernatant was isolated and 5% was reserved as the loading control. The remaining supernatant 
was diluted to 1.5 mL using lysis buffer supplemented with protease inhibitors and the protease 
inhibitor cocktail and ApoB was immunoprecipitated overnight with rotation at 4°C with 5 µL 
anti-ApoB (Millipore Sigma) antibody.  Incubations in the absence of added antibody served as a 
negative control.  All samples were then incubated with 50 µL Protein G Fast Flow Sepharose 
for 2 hours at room temperature and the beads were centrifuged at 5000 rpm for 2 minutes at 
4°C.  After the supernatant was removed, the beads were washed twice with lysis buffer and 
twice with lysis buffer supplemented with 300 mM NaCl.  Both solutions were supplemented 
with protease inhibitors and the protease inhibitor cocktail. The final, collected beads were 
resuspended in TCA sample buffer. Input samples were incubated with 10% TCA, incubated on 
ice 15 minutes, and centrifuged for 10 minutes at 14,000 rpm at 4°C in a microcentrifuge.  The 
final pellets were resuspended in TCA sample buffer using a mechanical pestle.  Input and IP 
samples were incubated at 37°C for 20 minutes, and subsequently subjected to SDS-PAGE and 
western blotting. Immunoblots were incubated with anti-HA, anti-Hsp104, anti-Ssa1, anti-Sse1, 
and anti-rpL5, as described above. 
 47 
2.1.9 In Vitro Retrotranslocation Assay  
The retrotranslocation efficiency and ubiquitination of ApoB was assessed based on a protocol 
previously published by our laboratory (Nakatsukasa et al. 2008).  In brief, medium scale 
microsomes were prepared from wildtype and hsp104Δ yeast expressing ApoB using the β-
estradiol system, as described above, and all cells were temperature shifted to 37°C for 1 hour 
prior to being collected.  ApoB expression was confirmed in the resulting microsomes, as 
described above.  A 40 µL in vitro reaction to assess ApoB ubiquitination and retrotranslocation 
was set up and consisted of Buffer 88, 4.0 µL of ApoB containing microsomes, and 5 mg/mL of 
yeast cytosol.  Where indicated, reactions included or lacked an ATP regenerating system.  After 
a 10 minute pre-incubation at room temperature, 6 µL of 125I-ubiquitin was added.  The reactions 
were then allowed to incubate for 45 minutes at 37°C.  Samples were centrifuged for 10 minutes 
at 4°C at 13,000 rpm in a refrigerated microcentrifuge.  The supernatant was removed and the 
pellet was resuspended in 40 µL of Buffer 88.  Next, all reactions were quenched with 125 µL of 
50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1.25% SDS supplemented with 10 mM NEM 
and protease inhibitors.  After a 30 minute incubation at 37°C, 400 µL of 50 mM Tris, pH 7.4, 
150 mM NaCl, 5 mM EDTA, 2% Triton X-100 supplemented with 10 mM NEM and protease 
inhibitors was then added to each reaction.  ApoB was immunoprecipitated overnight at 4°C 
using 35 µL Protein G Fast Flow Sepharose and 5 µL anti-ApoB antibody.  After the beads were 
collected, each sample was washed 3 times using 1 mL IP Wash buffer (50 mM Tris, pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.2%).  Proteins were eluted using 40 µL TCA 
sample buffer incubated at 37°C for 20 minutes.  Finally, the isolated proteins were resolved on 
duplicate 10% and 7.5% polyacrylamide gels and western blot analysis was conducted on the 
10% gel using anti-HA antibody.  Ubiquitination was assessed via phosphorimager analysis 
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using the dried 7.5% polyacrylamide gel.  Images were obtained using a Typhoon FLA 7000 
phosphorimager and the associated software.  
 
2.2 INVESTIGATION OF FACTORS THAT POTENTIALLY PREVENT 
APOLIPOPROTEIN B AGGREGATION 
2.2.1 Development and Characterization of a New ApoB Expression System 
To identify factors that regulate ApoB stability, our lab previously developed a galactose 
inducible expression system for use in the yeast Saccharomyces cerevisiae (Hrizo et al, 2007).  
However, galactose is a non-optimal carbon source and yeast cell growth is slowed during the 
time of induction, potentially creating an artificial stress and altered protein homeostasis, or 
“proteostasis” (Adams, 1972; Balch et al, 2008).  To improve upon our galactose-inducible 
ApoB29 expression system, I utilized the chimeric GEV transcription factor to regulate ApoB 
production via addition of β-estradiol (McIsaac et al, 2011).  The key to this system is the GEV 
transcription factor, a chimeric protein containing a Gal4 DNA binding domain, an Estrogen (β-
estradiol) binding domain, and a VP16 transcription factor (Figure 4A). As previously described, 
GEV is constitutively expressed and retained in the cytosol in an inactive form through Hsp90 
binding (McIsaac et al, 2011). Upon addition of β-estradiol, Hsp90 is released and GEV enters 
the nucleus by virtue of the VP16 fragment, where it promotes transcription of genes under the 
control of the GAL promoter.  This system can be created in any yeast strain by simply 
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integrating an expression vector for the chimeric protein into the genome and does not require 
carbon source switching. This provides the yeast with an optimal growth environment.   
To test the efficacy of this system, I first determined induction conditions for ApoB 
expression (Figure 4B). When an HA epitope-tagged form of ApoB is induced in wildtype cells 
using galactose, reasonable levels of ApoB are observed after 4-6 hours of induction via western 
blot analysis. In comparison, ApoB protein is observed as early as 5 minutes after using 1000 nM 
β-estradiol was added. To determine the optimal induction conditions using β-estradiol, wildtype 
cells containing the ApoB vector were next grown with various concentrations of β-estradiol. In 
the absence of β-estradiol, no ApoB is observed via western blot analysis. However, even at the 
lowest concentration of added β-estradiol (100 nM), ApoB is observed as early as 30 minutes 
after induction. I ultimately settled on the use of a 2 hour induction with 300 nM β-estradiol, as 
higher concentrations of β-estradiol and a longer time course does not lead to increased protein 
levels.  Importantly, the cells continued to replicate during these induction conditions, which is 
in stark contrast to the situation when the galactose inducible expression system is used. 
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(A)  A map of the Act1-GEV plasmid used to synthesize proteins under the control of the 
GAL promoter, which is activated in a β-estradiol dependent manner by a “GEV” fusion protein.  
The plasmid integrates into yeast strains at the leu2Δ0 locus and is selected by growth on media 
supplemented with 0.1 mg/mL Nourseothricin.  GEV consists of the Gal4 DNA binding domain, 
a fragment of the estrogen receptor, and the trans-activating components of the VP16 
transcription factor.   
(B) The ApoB29 protein was induced in wildtype yeast using either 2% galactose during a 12 
hour timecourse or in the presence of various concentrations of β-estradiol over a 120 min 
timecourse.  As no further increase was observed, 300 nM β-estradiol and a 120 min induction 
time were used for all further experiments.     
Figure 4. Comparison of ApoB29 Induction Conditions. 
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To validate our new expression system, I first tested if ApoB29 was an ERAD substrate 
after β-estradiol induction.  Our laboratory has previously published that this ApoB truncation , 
which still amasses lipids and traffics through the secretory pathway, is an ERAD substrate in 
yeast (Grubb et al, 2012; Hrizo et al, 2007). I therefore conducted cycloheximide chase assays in 
a pdr5Δ strain. Deletion of Pdr5 allows cells to accumulate a drug, MG132, which inhibits 
proteasome function and is otherwise pumped out of yeast cells (Balzi et al, 1994).  ApoB was 
expressed in pdr5Δ yeast and the cells were subsequently incubated in the presence or absence of 
MG132 using both the galactose inducible system and the β-estradiol inducible system.  In both 
induction systems, addition of MG132 stabilized ApoB levels relative to cells incubated in the 
absence of MG132 (Figure 5A).  The half-life of ApoB in the absence of MG132 using the β-
estradiol system is ~15 minutes while in the presence of MG132, its half-life is ~47 minutes.  I 
also calculated the effect of proteasome inhibition on each band individual (Figure 5B).  
Although the higher molecular weight species was degraded to a greater extent, upon addition of 
MG132 the levels of both  ApoB molecular weight species were stabilized compared to the cells 
incubated in the absence of MG132   I also found that degradation was more complete in the β-
estradiol system, which degraded to ~5%, whereas only ~40% of ApoB was degraded in the 
absence of MG132 using the galactose inducible system, as observed previously (Hrizo et al, 
2007).  Therefore, ApoB degradation is proteasome dependent regardless of which expression 
system is used.  
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Figure 5. ApoB Degradation is Proteasome Dependent Independent of the Expression System. 
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(A) A cycloheximide chase analysis was conducted in pdr5Δ yeast expressing ApoB after 
either a galactose (left) (N=9) or β-estradiol (right) (N=4) induction.  Yeast were incubated in the 
presence of MG132 (open circles) or in the absence of MG132 (closed circles) incubated at 
30°C.  At the indicated times, samples were taken and lysates were processed for immunoblot 
analysis using anti-HA antibody to detect ApoB.  G6PD serves as a loading control.  Examples 
of representative blots are shown below the data quantitation.  Asterisk denotes p < 0.05.    
(B) Data from Figure 5A β-estradiol induction were re-calculated to show the effect of 
proteasome inhibition on individual ApoB species.  Asterisk denotes p < 0.05.    
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An alternative method to degrade ApoB is by autophagy (Fisher et al, 2001).  However 
since yeast lack a functional MTP complex, I predicted there would be minimal contribution by 
autophagy.  Nevertheless, I investigated this possibility by conducting cycloheximide chase 
assays using yeast strains lacking both Pdr5 and Pep4 (Figure 6).  Pep4 is the main vacuolar 
protease, which activates downstream vacuolar proteases, that together with Pep4, degrade 
vacuole-targeted cargo proteins (Ammerer et al, 1986; Jones et al, 1982; Woolford et al, 1986).  
ApoB was expressed in wildtype or pep4Δpdr5Δ yeast and the cells were subsequently incubated 
in the presence or absence of MG132.  There was again profound stabilization of ApoB in 
pep4Δpdr5Δ yeast incubated with MG132 relative to cells lacking the drug, consistent with the 
data shown in Figure 6, however there was only modest stabilization of ApoB in pep4Δpdr5Δ 
yeast grown in the absence of MG132 compared to the wildtype cells. This effect was only 
apparent at early time points, and there was no significant difference in the extent of degradation 
by the end of the chase period.  These data indicate that the vacuole plays a minimal role during 
the degradation of ApoB in yeast.   
Because a substantial amount of ApoB appears to be degraded in both a vacuole-and 
proteasome-independent manner, at least with the β-estradiol induction system, it is possible that 
a fraction of ApoB is being secreted into the medium.  This hypothesis will be tested in the near 
future.  It is also possible that MG132 is still excreted from the cells or is being metabolized 
during the course of the experiment.  In addition, MG132 only inhibits the chymotrypsin-like 
activity of the proteasome (Lee & Goldberg, 1998).  It is possible that the trypsin-like and 
acidic/caspase-like protease functions of the proteasome can degrade ApoB, thus leading to the 
incomplete stabilization in the presence of MG132. 
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A cycloheximide chase analysis was conducted in wildtype (closed circles) (N=12) and 
pep4Δpdr5Δ yeast incubated in the presence of MG132 (closed squares) (N=12) and in the 
absence of MG132 (open squares) (N=12) incubated at 37°C.  At the indicated times, samples 
were taken and lysates were processed for immunoblot analysis using anti-HA antibody to detect 
ApoB.  G6PD serves as a loading control.  Examples of representative blots are shown below the 
data quantitation.  Asterisk denotes p < 0.05 relative to wildtype.    
Figure 6. The Vacuole Plays a Minor Role in ApoB Degradation. 
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The fact that ApoB is degraded at least in part in a proteasome-dependent manner when 
the protein is induced with β-estradiol is consistent with it being targeted for ERAD.  Another 
hallmark of an ERAD substrate is that ubiquitin ligases are essential to degrade the protein 
substrate (see section 1.4).   In yeast, the E3 ubiquitin ligases associated with ERAD are Hrd1 
and Doa10.  Hrd1 is required for the degradation of ERAD substrates with folding lesions in the 
ER lumen or membrane, while Doa10 is associated with ERAD substrates that have cytosolic 
lesions (Bays et al, 2001; Carvalho et al, 2006; Deak & Wolf, 2001; Denic et al, 2006; Swanson 
et al, 2001).  The E3 ubiquitin ligase requirements for ApoB in yeast have been previously 
investigated through the use of the galactose-inducible system (Rubenstein et al, 2012).  As 
might be predicted for an ERAD substrate whose degradation is dictated by an ER luminal 
“decision,” ApoB protein degradation was slowed in a HRD1 but not in a DOA10 mutant strain.  
Therefore to further validate the new expression system, I conducted cycloheximide chase 
analyses on wildtype yeast or yeast lacking Hrd1, Doa10, or both E3 ubiquitin ligases after 
ApoB was induced using β-estradiol (Figure 7).  As expected, ApoB degradation was slowed in 
hrd1Δ or hrd1Δdoa10Δ yeast while ApoB protein stability was unaffected in yeast lacking 
Doa10.  In this experiment, the extent of stabilization was significantly greater than observed 
when pdr5Δ cells were incubated with MG132 signifying that the other proteasome activities 
may also contribute to ApoB degradation.  Given that the β-estradiol induction system provides 
for a faster induction condition, does not compromise cell growth, yet still recapitulates the 
ERAD dependence of ApoB degradation, I used this new system for the remainder of my 
experiments.   
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A cycloheximide chase analysis was conducted in a wildtype yeast strain (N=10) (open 
circles), or in yeast lacking Hrd1 (N=11) (closed circles), Doa10 (N=10) (open squares), or Hrd1 
and Doa10 (N=12) (closed squares) incubated at 30°C.  At the indicated times, samples were 
taken and lysates were processed for immunoblot analysis using anti-HA antibody to detect 
ApoB.  G6PD serves as a loading control.  Asterisk denotes p < 0.05.  Upper asterisks denote 
hrd1Δdoa10Δ relative to wildtype and lower asterisks indicate hrd1Δ relative to wildtype.  
Examples of representative blots are shown below the data quantitation. 
Figure 7. Hrd1 is an E3 Ubiquitin Ligase For ApoB. 
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2.2.2 The Two ApoB29 Species Reside in Different Cellular Locations 
In both expression systems, ApoB appears as a doublet via western blot.  Since most secretory 
proteins (including ApoB) are glycosylated as they transit into the ER, differential glycosylation 
may explain the nature of the doublet (Harazono et al, 2005). I first investigated this hypothesis 
through the use of an enzyme, EndoglycosidaseH (EndoH), which removes N-linked 
glycosylation from proteins residing in the ER (Maley et al, 1989).  Lysates were prepared from 
wildtype cells expressing ApoB and incubated in the presence or absence of EndoH (Figure 8A).  
As a positive control, Pdi1, a glycosylated ER resident protein was also examined (Farquhar et 
al, 1991; Mizunaga et al, 1990).  I first found that migration of Pdi1 following SDS-PAGE was 
faster after incubation with EndoH.  In contrast, this enzyme had no effect on G6PD, which is an 
unglycosylated cytosolic protein. Upon incubation with EndoH, the ApoB higher molecular 
weight species shifted down by ~6 kDa while the lower band remained unchanged. Because 
there are 2 predicted glycosylation sites in ApoB29, this molecular weight shift corresponds to 
both sites being used (Harazono et al, 2005). Therefore, this species has entered the ER to a 
sufficient extent that these sites (at amino acids 158 and 956) have been post-translationally 
modified with N-glycans.  As the lower molecular weight species was unaffected by EndoH, 
possible explanations include the upper band containing additional types of post-translational 
modifications or the lower band is a truncated form of ApoB and does not translocate far enough 
into the ER to be glycosylated.  Because the ApoB29 used in these studies contains the HA tag at 
the C-terminus, the N-terminus of the protein would be absent from this lower molecular weight 
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species.  Notably, the N-terminal truncated species would lack the signal sequence which would 
also explain why the protein could not be translocated into the ER.   
I was then curious if ApoB required deglycosylated prior to proteasome-mediated 
degradation.  I explored this question by conducting cycloheximide chase assays in wildtype and 
png1Δ yeast expressing ApoB (Figure 8B).  Png1 is the enzyme responsible for removing N-
linked glycans following retrotranslocation but before degradation, and the removal of N-glycans 
has been proposed to be essential to allow a polypeptide to access the 20S core of the proteasome 
(Hirsch et al, 2003; Huppa & Ploegh, 1997; Suzuki et al, 2000; Suzuki et al, 1998; Wang et al, 
2009).  However, the degradation of most ERAD substrates appears to be unaffected by the 
absence of Png1 (Blom et al, 2004; Hosomi et al, 2016; Kario et al, 2008; Kim et al, 2006)    
Consistent with these studies, deletion of Png1 did not affect ApoB degradation, except perhaps 
at a single early timepoint.   
To better define the characteristics of the two ApoB species, I conducted limited 
proteolysis on ER-derived microsomes prepared from yeast expressing ApoB (Figure 9A). 
Microsomes were combined with a small amount of protease or buffer on ice.  During a 10 
minute incubation, samples were removed and processed for immunoblot analysis.  Upon 
incubation with Proteinase K, Sec61, an ER-resident protein, and Kar2, an ER luminal 
chaperone, were stable during the incubations as anticipated.  In contrast, the higher molecular 
species of ApoB was stable while the lower molecular weight species of ApoB was degraded in 
the presence of Proteinase K.  This result indicates that the higher molecular weight ApoB 
species band is most likely protected inside the microsomes, consistent with its glycosylation 
pattern. In contrast, the lower molecular weight species was accessible to Proteinase K,  
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(A) Lysate from wildtype yeast expressing ApoB was incubated in the presence or absence of 
EndoH. G6PD, a cytosolic protein, is unaffected by EndoH while PDI, an N-glycosylated 
protein, migrates at a lower molecular weight upon incubation with EndoH.  The lower 166 kDa 
species of ApoB remains unaffected by EndoH while the upper band migrates at a slightly lower 
molecular weight after treatment.   
(B) A cycloheximide chase analysis was conducted in wildtype (closed circles) (N=12) and 
png1Δ (open circles) (N=12) yeast expressing ApoB incubated at 30°C.  At the indicated times, 
samples were taken and lysates were processed for immunoblot analysis using anti-HA antibody 
to detect ApoB.  G6PD serves as a loading control.  Examples of representative blots are shown 
below the data quantitation.  Asterisk denotes p-value <0.05.  
Figure 8. A Higher Molecular Weight ApoB Species is Glycosylated in Yeast. 
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confirming that it has not translocated into the ER and remains  outside the microsomal 
membrane. 
Next, I asked whether the lower molecular weight species might be partially aggregated 
since it failed to enter the ER and acquire N-linked glycans.  Previous work indicated that 
resistance to carbonate extraction can be used to determine whether a protein resides within a 
lipid bilayer or is aggregation prone (Anderson & Denny, 1992; Fujiki et al, 1982; Le Parc et al, 
2010).  I therefore conducted carbonate extractions on ER-derived microsomes prepared from 
yeast expressing ApoB.  The membranes were mixed with either buffer or sodium carbonate, and 
the mixture was then centrifuged to resolve the soluble and precipitated material (Figure 9B). 
When mixed with buffer, Sec61, Pdi1, and both ApoB species were found in the pellet fraction. 
Upon incubation with sodium carbonate, Pdi1 was found in the supernatant fraction while Sec61 
was found in the pellet fraction, as expected. Interestingly, the lower molecular weight ApoB 
species was found in the pellet fraction while the higher molecular weight species resided in the 
supernatant fraction. I hypothesize that the upper band has entered the ER but a portion of the 
protein remains in the aqueous confines of the Sec61 translocon and is therefore accessible to the 
carbonate (Gilmore & Blobel, 1985).  This is the topology expected for an ApoB species that is 
poised to either become lipid-loaded or retrotranslocated and degraded (Davis et al, 1990; Dixon 
et al, 1991; Fisher et al, 2008; Fisher et al, 1997; Pariyarath et al, 2001).  However, the lower 
band is an untranslocated species that remains outside but perhaps associated with the ER and is 
aggregation prone.  Because some disease causing mutations in ApoB similarly prevent the 
translocation of ApoB into the ER, this untranslocated species may serve as a model to 
understand the properties of these variants (Blackhart et al, 1986; Sturley et al, 1994).  
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(A) ER derived microsomes were prepared from wildtype yeast expressing ApoB and 
subjected to limited proteolysis with Proteinase K (ProK) as indicated.  Samples were incubated 
with protease at a final concentration of 0.04 mg/mL or buffer at 4°C and samples were 
processed at the indicated times for immunoblot analysis using anti-HA, anti-Kar2, and anti-
Sec61 antibodies.  The lower molecular weight species of ApoB is degraded by ProK while the 
upper band is protected.  Kar2, an ER luminal Hsp70, and Sec61, an integral membrane protein, 
are protected from Proteinase K digestion.   
Figure 9. Different Forms of ApoB are Differentially Localized. 
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(B) Sodium carbonate extraction was conducted with lysates from wildtype yeast expressing 
ApoB.  Upon treatment with sodium carbonate, the ER resident and soluble protein, PDI, is 
found in the supernatant fraction whereas the membrane protein, Sec61, is found in the pellet 
fraction.  In contrast, the higher molecular weight ApoB species is found in the supernatant 
fraction while the lower molecular weight species is found in the pellet fraction.   
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To establish if the lower molecular weight ApoB species was an untranslocated species, I 
wanted to create a mutant version of ApoB that completely lacks a signal sequence.  As a first 
step, I conducted sequence analysis on pSLW1-B9-HA as I only had minimal details on the 
creation of the plasmid.  Based on the methods outlined in Hrizo et al, 2007, I first compiled the 
predicted sequence, which should include the prepro-alpha factor signal sequence and then the 
full sequence of ApoB29, using the freely available databases from NCBI and the 
Saccharomyces genome database.  However, upon comparing the predicted sequence with my 
results from direct DNA sequence analysis, a few discrepancies were identified (Figure 10).  
First, the ApoB29 sequence started at basepair 96 but not basepair 81 (both of which are after the 
signal sequence), and ended at basepair 4113 but not basepair 4122 as reported.  Additionally, 
one of the primers used to clone APOB29 was lacking an amino acid compared to the reference 
sequence.  Second, the signal sequence was reported to contain nucleotides 1-300 from prepro-
alpha factor but only contained nucleotides 1-212.  Third, due to the missing DNA sequence, 
there appears to be a frameshift that would truncate the protein if both the signal sequence and 
ApoB29 were translated.  Nevertheless, the upper band is the correct size for ApoB29 and 
exhibits each of the characteristics expected for the protein: it is properly glycosylated, has 
translocated into the ER, is recognized by a C-terminal epitope, and remains soluble.  In contrast, 
the lower molecular weight species also harbors the C-terminal epitope but appears to lack a 
signal sequence since it cannot be translocated.  I propose that this species uses an alternative 
start site found in ApoB, which produces an ApoB protein that lacks a signal sequence and may 
be partially compensated for by the strong promoter.  In the coming months, I will be working to 
create a plasmid that contains the full length signal sequence properly fused to the ApoB29 
sequence, as well as a form of ApoB that completely lacks a signal sequence.   
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The reported ApoB29 construct contains the signal sequence from prepro-alpha factor 
(basepair 1-300), the N-terminal 29% of ApoB (basepair 81-4122 which lacks the ApoB signal 
sequence), two glycosylation sites (orange triangles), and a triple HA tag (Hrizo et al. 2007).  
Upon sequence analysis, the ApoB29 construct contains basepairs 1-212 for the signal sequence 
from prepro-alpha factor (which includes the complete signal sequence and part of the pro 
region), basepairs 96-4113 from ApoB, two glycosylation sites (orange triangles), and a triple 
HA tag.  The predicted translation of the obtained sequence results using the first methionine in 
Figure 10. ApoB Sequence Predictions. 
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the signal sequence would result in multiple stop codons in the signal sequence and ApoB29 and 
the generation of small protein species.  The predicted translation of the sequencing results using 
the methionine in ApoB would result in an ApoB protein containing the triple HA tag but lacking 
a signal sequence.  We propose that the translation is corrected in part by the strong promoter but 
the frameshift probably decreases translation efficiency. Since the sequencing was only 
conducted once on one strand, it is formally possible that these issues could arise from a wrong 
sequence result. 
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2.2.3 ApoB is Absent From Lipid Droplets  
Even though the existing expression plasmids synthesize a protein that appear to lack a signal 
sequence or contain a few mutations relative to the native ApoB29 sequence, I propose that these 
proteins are still a valid model to investigate the ERAD of ApoB, as ApoB behaves as an ERAD 
substrate and we have previously identified factors using this ApoB29 construct in yeast that also 
affect ApoB in mammalian cells.  Therefore, I used these proteins to investigate factors that may 
regulate ApoB’s solubility after retrotranslocation.  As ApoB is a large, amphipathic protein, I 
hypothesize that cytosolic factors must be present to prevent its aggregation after 
retrotranslocation but before degradation.  I first hypothesized that lipid droplets could interact 
with ApoB to prevent its aggregation. Lipid droplets are highly conserved organelles that contain 
the largest concentration of lipids present in the cell. These lipids, which include triacylglycerols 
and sterol esters, are thought to be storage compartments for use during cell stress and starvation 
(Brasaemle & Wolins, 2012; Carman, 2012; Farese & Walther, 2009; Goodman, 2008; Murphy, 
2012). Other aggregation prone proteins, such as α-synuclein which is implicated in Parkinson’s 
disease, have been shown to interact with lipid droplets en route to degradation (Cole et al, 2002; 
Scherzer & Feany, 2004).   
ApoB has also been proposed to interact with lipid droplets in mammalian cells 
(Fujimoto & Ohsaki, 2006; Ohsaki et al, 2006; Ohsaki et al, 2008; Suzuki et al, 2012). Using 
Huh7 cells expressing fluorescently tagged ApoB, ApoB localized to areas near the surface of 
lipid droplets, which were termed crescents. The authors of these studies subsequently went on to 
show that ApoB remained associated with these crescents until they were broken down by 
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proteasomal degradation or autophagy. In addition, the crescents appeared to increase under 
conditions that promoted ApoB degradation either by autophagy or ERAD. However, even 
though Huh7 cells are a hepato carcinoma cell line, they do not normally express ApoB and do 
not lipidate ApoB without exogenously added lipids. The majority of ApoB that is secreted is 
incorporated into particles with the density of LDLs and HDLs (Meex et al, 2011). Therefore, 
this system may not be a representative model for ApoB secretion. 
Even though the yeast system similarly suffers from an inability to endogenously 
synthesize ApoB and assemble lipoproteins, the robust level of ERAD I observed in this model 
suggests that ApoB may similarly reside in lipid droplets.  However, other data suggest that lipid 
droplets appear to be dispensable for ERAD, as model ERAD substrate degradation was 
unaffected by the absence of lipid droplets (Nakatsukasa & Kamura, 2016; Olzmann & Kopito, 
2011; To et al, 2017) 
To address this controversy, I first investigated if ApoB resides in lipid droplets through 
the use of sucrose gradient sedimentation.  Sucrose gradient sedimentation allows for the 
identification of subcellular localization of proteins.  By determining where proteins of known 
cellular location reside within the sucrose gradient, I can determine in principle where ApoB is 
localized in the cell.  Therefore, if ApoB interacts with lipid droplets, it should co-migrate with a 
lipid droplet resident protein.  I first conducted sucrose gradient sedimentation in wildtype yeast 
and lipid droplet deficient yeast.  Lipid droplet synthesis occurs at the ER, as the enzymes 
needed for neutral lipid synthesis, Are1, Are2, Dga1 and Lro1, are localized to the ER membrane 
(Oelkers et al, 2002; Oelkers et al, 2000; Yang et al, 1996; Zweytick et al, 2000).  Therefore, a 
yeast strain was created in which each enzyme is individually deleted (Sandager et al, 2002).  
This strain grows slowly but is viable.   
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Lysate from wildtype yeast and lipid droplet deficient yeast expressing ApoB using the 
galactose inducible expression system was placed onto a discontinuous 20-70% sucrose gradient.  
The gradients were ultracentrifuged, fractionated, and subjected to SDS-PAGE followed by 
western blot analysis.  We analyzed the localization of Anp1, Sec61, and Pma1 to determine 
where specific membranes reside in the gradient.  Anp1 is a member of the α-1,6 
mannosyltransferase complex in the Golgi apparatus (Chapman & Munro, 1994; Jungmann et al, 
1999; Melnick & Sherman, 1993).  Sec61 is an ER resident protein and is the main component of 
the translocon (Deshaies & Schekman, 1987; Zhou & Schekman, 1999).  Pma1 is a plasma 
membrane resident ATPase (Perlin et al, 1988; Serrano et al, 1986).  In wildtype yeast, peak 
Anp1 is found in fractions 8-11, peak Sec61 is found in fractions 12-17, and peak Pma1 is found 
in fractions 14-19 (Figure 11A).  ApoB is found throughout the gradient, in fractions 4-20.  As 
there was a population of ApoB (fractions 4-7) that was even less dense than the Golgi, I initially 
hypothesized that these fractions contained ApoB that may interact with lipid droplets.  In the 
lipid droplet deficient yeast, the Anp1 enriched fractions are 11-15, the Sec61 peak fractions are 
14-19, and Pma1 is primarily found in fractions 12-17 (Figure 11B).  ApoB is found throughout 
the gradient, in fractions 6-19.  Again, there was a population of ApoB that was even less dense 
than the Golgi.  However, this was not true of all lipid droplet deficient gradients.  Some of the 
gradients lacked this population that was less dense than the Golgi (data not shown).     
Based on these inconsistencies, I next determined lipid droplet localization in a sucrose 
gradient.  Lysate from a wildtype strain with an integrated copy of Tgl3-GFP was placed onto a 
discontinuous sucrose gradient, consisting of 10%, 35%, 50%, and 70% magnesium-containing 
sucrose (Figure 11C).  Tgl3 is a lipid droplet resident protein and is responsible for the majority 
of lipase activity in lipid droplets (Athenstaedt & Daum, 2003; Schmidt et al, 2013). 
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(A)  Lysate from wildtype yeast expressing ApoB using the galactose inducible expression 
system was subject to 10-70% magnesium-containing sucrose gradient sedimentation.  Gradients 
were fractionated and samples were subjected to immunoblot analysis using anti-HA, anti-Anp1, 
anti-Sec61, and anti-Pma1 antibodies.  The identities of each protein in the gradient are shown.   
Figure 11. ApoB is Localized Throughout a Sucrose Gradient. 
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(B) Lysate from lipid droplet deficient yeast (are1Δare2Δlro1Δdga1Δ) expressing ApoB 
using the galactose inducible expression system was subject to sucrose gradient sedimentation as 
in (A).    
(C) Lysate from a wildtype yeast strain containing an integrated copy of Tgl3-GFP 
expressing ApoB was subject to sucrose gradient sedimentation as above.  The gradient 
contained steps of 10%, 35%, 50% and 70% magnesium-containing sucrose.  Gradients were 
fractionated and samples were subjected to immunoblot analysis using anti-HA, anti-GFP, anti-
Anp1, anti-Sec61, and anti-Pma1 antibodies.   
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 In this experiment, I altered the steps of the gradient to better separate the fractions containing 
the Golgi and the ER.  In this experiment, the Anp1 peak is found in fractions 12-14, the Sec61 
peak is found in fractions 20-23, and the Pma1 peak is found in fractions 21-23.  The majority of 
Tgl3 is localized to fractions 4-15.  Once again, ApoB is found throughout the gradient, but the 
majority is present in fractions 8-15.  While these gradients were supportive of the idea that 
ApoB interacts with lipid droplets, the extensive spreading of the lipid droplets and ApoB 
throughout the gradients – perhaps because of their hydrophobic nature – made it difficult to 
make definitive conclusions.  In addition, the data were often inconsistent and did not yield a 
definitive answer to where ApoB is localized.   
Therefore, I next determined if ApoB localizes to lipid droplets in yeast by performing a 
large scale lipid droplet isolation (Leber et al, 1994).  This isolation protocol involved 
spheroplasting yeast to remove cell walls, followed by passing the lysate over a series of Ficoll 
and Sorbitol containing gradients to separate lipid droplets from other subcellular compartments 
(Figure 12).  The final gradient is especially important as vacuoles and lipid droplets are two of 
the least dense cellular compartments and are often difficult to separate.  As the particles are 
heavily enriched in lipids, a TCA precipitation must also be conducted to remove the lipids in 
order to visualize proteins via western blot analysis.  
The lipid droplet isolation was conducted using a wildtype yeast strain expressing ApoB 
that also contained an integrated copy of Tgl3-GFP (Figure 13).  To determine the purity of 
select fractions, the presence or absence of several proteins was assayed.  I found that Tgl3, a 
lipid droplet resident lipase (see above), was present in my preparation of the highly enriched 
lipid droplets. In contrast, Vph1, a vacuolar protein, was absent from my preparations of the  
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To isolate lipid droplets from yeast, yeast cell walls were removed using lyticase for 15 
minutes in a 30°C shaking water bath.  Following collection, yeast cells were lysed in buffer 
containing 12% Ficoll using a Dounce homogenizer.  Following 2-fold dilution in buffer 
containing 12% Ficoll, lysate was ultracentrifuged for 1 hour at 100,000g.  Vacuoles and crude 
lipid droplets were isolated from the top of the gradient, diluted 2 fold, and mixed in a Dounce 
homogenizer.  The solution was then overlaid with a solution containing 8% Ficoll and 
ultracentrifuged for 1 hour at 100,000g.  Lipid droplets and vacuoles were isolated from the top 
of the gradient, diluted 2 fold in buffer containing 8% Ficoll and 0.6 M Sorbitol.  This solution 
was next overlaid with buffer containing 0.25 M Sorbitol and ultracentrifuged for 30 minutes at 
100,000g.  Highly enriched lipid droplets were isolated from the top of the gradient, delipidated 
through TCA precipitation, and subjected SDS-PAGE followed by western blot analysis.   
Figure 12. Isolation of Yeast Lipid Droplets. 
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Lipid droplets were isolated from a wildtype yeast strain expressing ApoB and containing 
an integrated copy of Tgl3-GFP.  Fractions representing the crude homogenate, the first 5,500 
rpm pellet fraction following Dounce homogenization, or the highly enriched lipid droplet 
fraction were obtained and examined by immunoblot analysis using anti-HA, anti-GFP, anti-
Vph1, and anti-Sec61 antibodies.  Tgl3 is a lipid droplet resident protein, Vph1 is a resident 
vacuole protein, and Sec61 is an ER resident protein.   
Figure 13. ApoB is Absent From Lipid Droplets. 
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highly enriched lipid droplets, indicating that the lipid droplet preparation was not contaminated 
with vacuoles. Furthermore, Sec61, an ER resident protein, was absent from lipid droplet 
fraction but was found in the homogenate and pellet fractions. I found that ApoB behaved like 
Sec61, residing only in the homogenate and pellet fractions but not the lipid droplet fraction. 
These results rule out the possibility that a significant amount of ApoB resides in lipid droplets in 
yeast, but the protein is instead primarily an ER resident. 
2.2.4 The Small Heat Shock Proteins Do Not Affect ApoB Stability 
Because ApoB does not appear to reside in lipid droplets, I next hypothesized that cytosolic 
factors, such as specific molecular chaperone “holdases”, could interact with ApoB in the 
cytoplasm after retrotranslocation.  Chaperone “holdases” are molecular chaperones that tightly 
bind to misfolded or unfolded polypeptides to prevent irreversible protein aggregation in a non-
catalytic manner (Mattoo & Goloubinoff, 2014).  One such family of these chaperones is the 
small heat shock proteins. The small heat shock proteins are ATP-independent and prevent 
protein aggregation via physically interacting with their substrates through a characteristic C-
terminal α-crystallin domain (Burnie et al, 2006; Petko & Lindquist, 1986; Wotton et al, 1996).  
The small heat shock proteins are conserved from yeast to humans, which encode at least 10 
family members (Bakthisaran et al, 2015; Kappe et al, 2003).  In yeast, however, there are two 
small heat shock proteins, Hsp26 and Hsp42.  Hsp26 is stress inducible (Susek & Lindquist, 
1990; Tuite et al, 1990). In contrast, Hsp42 is constitutively expressed and is required to direct 
proteins to cytosolic aggregates (Haslbeck et al, 2004; Specht et al, 2011).  
Previously, the small heat shock proteins were shown to facilitate the degradation of 
another ERAD substrate in yeast, the Cystic Fibrosis Transmembrane conductance Regulator 
 76 
(CFTR) (Ahner et al, 2007).  Deletion of Hsp26 slowed CFTR degradation while deletion of 
both small heat shock proteins almost completely stabilized CFTR.  Consistent with this, the 
authors also observed that overexpression of a human small heat shock protein, αA-crystallin, 
enhanced degradation of CFTR in transfected HEK293 cells.  Purified α-crystallin also slowed 
the aggregation of NBD1 in CFTR.  Therefore, I hypothesized that the small heat shock proteins 
may also affect ApoB degradation, which is similarly aggregation prone. To investigate this 
hypothesis, I, with the help of an undergraduate, Ashley French, assayed ApoB stability in yeast 
strains that lack Hsp26 and/or Hsp42 (Figure 14). Cycloheximide chase assays were performed 
in wildtype, hsp26Δ, hsp42Δ, and hsp26Δhsp42Δ cells expressing ApoB under the control of the 
β-estradiol system.  However, no effect on the ApoB degradation rate was observed in the 
absence of these chaperones, indication the small heat shock proteins do not affect ApoB 
degradation.   
2.2.5 TRiC Does Not Affect ApoB Stability 
The next chaperone “holdase” I investigated is the Tcp-1 Ring complex (TRiC).  TRiC is a group 
II chaperonin and Hsp60 family member, which forms a large octameric complex to help refold 
proteins in an ATP-dependent manner.  TRiC recognizes substrates through hydrophobic 
regions, electrostatic interactions, and/or polar motifs (Dunn et al, 2001; Kalisman et al, 2013; 
Spiess et al, 2004; Zhuravleva & Radford, 2014).  The heteromeric complex forms a pore with a 
built-in lid and provides a favorable environment to facilitate protein folding.  TRiC is required 
to help fold 5-10% of newly synthesized and aggregation-prone proteins, including huntingtin, 
actin, and tubulin, and helps fold β-strand-rich regions in proteins (Joachimiak et al, 2014; 
Nollen et al, 2004; Shahmoradian et al, 2013; Sontag et al, 2013; Ursic & Culbertson, 1991; 
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Ursic et al, 1994; Yam et al, 2008).  As ApoB is also β-sheet rich, I hypothesized that TRiC may 
similarly play a role during ApoB folding or degradation.   
I had previously investigated TRiC’s effect on ApoB using the galactose inducible 
expression system and observed a small but reproducible effect on ApoB degradation rates at the 
final 90 minute timepoint, although this difference was not statistically significant (data not 
shown).  I therefore investigated the effect of TRiC depletion on ApoB stability with my new β-
estradiol expression system.  I consequently conducted cycloheximide chase assays on wildtype 
and a temperature-sensitive mutation of TRiC (tcp1 mutant strain) expressing ApoB (Figure 15).  
After shifting to the non-permissive temperature,  no effect on ApoB degradation rates, 
indicating that TRiC is dispensable for the ERAD of ApoB.  These results suggest that the 
modest effect of galactose on ApoB degradation might have arisen from a defect in 
growth/viability or the added stress of growth on galactose. 
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A cycloheximide chase analysis was conducted in a wildtype yeast strain (N=7) (open 
circles), yeast lacking Hsp26 (N=11) (closed circles), Hsp42 (N=7) (open squares), or Hsp26 and 
Hsp42 (N=11) (closed squares) incubated at 37°C.  At the indicated times, samples were taken 
and lysates were processed for immunoblot analysis using anti-HA antibody to detect ApoB.  
G6PD serves as a loading control.  Examples of representative blots are shown below the data 
quantitation. 
Figure 14. The Small Heat Shock Proteins Do Not Affect ApoB Stability. 
 79 
  
2.2.6 Hsp104 is a Pro-degradation Factor for ApoB 
Another chaperone holdase and disaggregase is  Hsp104. Hsp104 is a hexameric AAA+ ATPase 
that helps refold aggregated proteins (Glover & Lindquist, 1998; Lee et al, 2004; Parsell et al, 
1991; Sanchez et al, 1992; Zolkiewski et al, 2012).  Hsp104 is essential for yeast survival under 
extreme stress conditions and for the propagation of yeast prions (Chernoff et al, 1995; Sanchez 
& Lindquist, 1990; Sanchez et al, 1992; Shorter & Lindquist, 2004).  .  Hsp104 is also thought to 
supply the mechanical force necessary to remove aggregated proteins from cellular aggregates. 
The protein substrate passes through the central pore of Hsp104 where it can interact with Hsp70 
and Hsp40 to be refolded (Glover & Lindquist, 1998; Heuck et al, 2016; Lee et al, 2004; Yokom 
et al, 2016; Zolkiewski et al, 2012). This may help confer thermotolerance to the cell, as Hsp104 
levels increase 8-10 fold between 30 mins and 2 hours of heat shock  (Newnam et al, 2011).  
Since more Hsp104 is present, it may help dissolve aggregates formed during stress conditions.  
Curiously, Hsp104 has no direct sequence homolog in metazoans but is conserved across 
bacteria, archea, fungi, and plants. To compensate for this loss, Hsp110, Hsp70, and Hsp40 
cooperate to prevent protein aggregation in metazoans (Glover & Lindquist, 1998; Mattoo et al, 
2013; Parsell et al, 1991; Rampelt et al, 2012; Shorter, 2011; Shorter, 2017; Torrente & Shorter, 
2013).  More recent studies indicate that this activity is magnified when interacting Hsp40 
partners with different chemical features are used in combination (Nillegoda et al, 2015).
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A cycloheximide chase analysis was conducted in wildtype (N=11) (closed circles) and 
tcp1-2 (N=12) (open circles) yeast expressing ApoB incubated at 37°C.  At the indicated times, 
samples were taken and lysates were processed for immunoblot analysis using anti-HA antibody 
to detect ApoB.  G6PD serves as a loading control. Examples of representative blots are shown 
below the data quantitation. 
Figure 15. ApoB Degradation is Unaffected By the Absence of TRiC. 
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Hsp104 consists of 6 subunits, each containing an N-terminal domain (NTD), a middle 
(M) domain, two nucleotide binding domains (NBD1, NBD2), and a C-terminal domain (CTD).  
The NTD is a flexible region containing a long linker that has been implicated as a site for 
substrate interaction (Barnett et al, 2005; Doyle et al, 2012; Rosenzweig et al, 2015).  Each NBD 
contains two AAA+ domains, which also interact with substrate to provide the energy for protein 
translocation, and comprise the ATP binding site. Additionally, the AAA+ domains consist of 
the conserved Walker A and B motifs, sensor-1 and sensor-2, and an arginine finger (Kedzierska 
et al, 2003; Lee et al, 2007; Rosenzweig et al, 2013; Zolkiewski et al, 2012).  The NBD1 may 
also help to determine substrate specificity (Johnston et al, 2017).  The M domain interacts with 
Hsp70, helps with communication between the NBDs, and is required for protein disaggregation 
(Cashikar et al, 2002; Desantis et al, 2014; Lee et al, 2013; Seyffer et al, 2012; Sielaff & Tsai, 
2010).  Recent cryo-EM structures of the M domain place it in close contact with NBD1.  With 
individual Hsp104 subunits aligned next to each other, the M domain can essentially wrap 
continuously around the structure in order to regulate oligomeric function.  Hsp70 can bind the 
M domain, causing a conformational shift and resulting in Hsp104’s ability to interact with 
substrate (Heuck et al, 2016). The CTD is required for oligomerization of the subunits (Mackay 
et al, 2008).   
Recent cryo-EM structures of Hsp104 from Saccharomyces cerevisiae and crystal 
structures from Chaetomium thermophilian, a filamentous yeast, have offered new insights into 
Hsp104’s ability to disaggregate proteins (Heuck et al, 2016; Yokom et al, 2016).  Instead of 
forming a closed cylinder, each subunit is tilted slightly and rotates approximately 53°, causing a 
corkscrew pattern to form and resulting the in final structure to rise nearly 10 Å from beginning 
to end.  Nevertheless, the first and last subunit can interact, although this requires movement of 
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nearly 100°, forming a seam on the structure.  Each NBD1 interacts with the M domain from the 
previous subunit to regulate movement.  Following ATP hydrolysis, the substrate can be passed 
to NBD2 in the same subunit.  After another round of hydrolysis, the substrate is passed to the 
adjacent subunit’s NBD1.  In this way, the substrate is passed through the channel, in a step like 
fashion.       
To investigate if Hsp104 affects ApoB stability, I again worked with Ashley French, and 
we conducted cycloheximide chase assays on wildtype and hsp104Δ yeast expressing ApoB, 
which were temperature shifted to 37°C to induce stress, which is when Hsp104 activity is most 
essential (Figure 16A). Upon temperature shift, ApoB was significantly stabilized in the absence 
of Hsp104 throughout the chase period.  To determine if Hsp104 affected ApoB stability under 
non-stress conditions, I therefore conducted cycloheximide chase assays In wildtype and 
hsp104Δ yeast expressing ApoB incubated at 30°C (Figure 16B).  Under these conditions, 
Hsp104 had no effect on ApoB stability, indicating that Hsp104 is only important during stress.  
As Hsp104 is also required for yeast prion propagation, I wanted to ensure that the effect 
Hsp104 exerted on ApoB was not due to the presence of prions, which might recognize ApoB 
aggregates (Chien & Weissman, 2001).  I therefore cured putative prions in wildtype and 
hsp104Δ yeast by growing them on YPD media containing 3 mM guanidine hydrochloride.  
Millimolar amounts of guanidine hydrochloride prevent prions from forming and replicating new 
prions (Eaglestone et al, 2000; Jung et al, 2002; Tuite et al, 1981).  Following the curing of the 
strains, I conducted cycloheximide chase assays on wildtype and hsp104Δ yeast expressing 
ApoB that were temperature shifted to 37°C (Figure 16C).  Upon temperature shift, ApoB 
degradation was again significantly stabilized in the absence of Hsp104 throughout the chase 
period.   
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(A) A cycloheximide chase analysis was conducted in wildtype (closed circles) (N=10) and 
hsp104Δ (open circles) (N=9) yeast expressing ApoB incubated at 37°C.  At the indicated times, 
samples were taken and lysates were processed for immunoblot analysis using anti-HA antibody 
Figure 16. Hsp104 Stabilizes ApoB Degradation Under Stress Conditions. 
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to detect ApoB.  G6PD serves as a loading control.  Examples of representative blots are shown 
below the data quantitation.  Asterisk denotes p < 0.05.    
(B) A cycloheximide chase analysis was conducted in wildtype (closed circles) (N=11) and 
hsp104Δ (open circles) (N=15) yeast expressing ApoB incubated at 30°C.  At the indicated times, 
samples were taken and lysates were processed for immunoblot analysis using anti-HA antibody 
to detect ApoB.  G6PD serves as a loading control.  Examples of representative blots are shown 
below the data quantitation.   
(C) Wildtype and hsp104Δ yeast were cured of prions by growth on YPD supplemented with 
3 mM guanidine hydrochloride.  A cycloheximide chase analysis was conducted in prion cured 
wildtype (closed circles) (N=11) and hsp104Δ (open circles) (N=15) yeast incubated at 37°C.  At 
the indicated times, samples were taken and lysates were processed for immunoblot analysis 
using anti-HA antibody to detect ApoB.  G6PD serves as a loading control.  Examples of 
representative blots are shown below the data quantitation.  Asterisk denotes p < 0.05.       
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  Since I had determined that ApoB species in the doublet exhibit different characteristics, 
I was curious if Hsp104 had differing effects on the glycosylated (ER soluble) species versus the 
non-glycosylated (aggregation-prone, cytoplasmic) species.  The data in Figure 16A display the 
degradation rates for both bands.  Therefore, I next calculated the degradation rates of the 
glycosylated or non-glycosylated versions alone and found that Hsp104 significantly affected the 
stability of both ApoB species (Figure 17).  However, the non-glycosylated band was more 
dependent on Hsp104 for degradation than the glycosylated band, which is perhaps consistent 
with the more aggregation-prone nature of this species (Figure 17 right).   
Because the loss of Hsp104 might affect secondary processes within the cell, I next 
sought to determine if Hsp104 was directly involved in degradation. I first investigated the direct 
role of Hsp104 on ApoB ERAD by conducting cycloheximide chase assays in wildtype or 
hsp104Δ cells that expressed ApoB and either expressed Hsp104 from a plasmid or that 
contained a vector control (Figure 18). After the cells were temperature shifted to 37°C, ApoB 
was again significantly stabilized in hsp104Δ cells containing a vector control compared to 
wildtype cells containing the same vector control. Importantly, ApoB degradation rates returned 
to the wildtype level upon expression of Hsp104 in hsp104Δ cells.  Upon Hsp104 overexpression 
, ApoB was degraded to an even greater extent. These data strongly suggest that Hsp104 directly 
facilitates ApoB degradation.  
To establish further that the effect of Hsp104 on ApoB stability is direct, I next tested if 
ApoB interacts with Hsp104 via coimmunoprecipitation experiments (Figure 19).  Lysate from 
wildtype cells expressing ApoB was incubated in the presence or absence of a commercial anti-
ApoB antibody and the associated proteins were isolated. As shown in Figure 19, I found that two 
chaperones previously shown to bind ApoB, Ssa1 (Hsp70) and Sse1 (Hsp110), were enriched 
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Data from Figure 16A were re-calculated to show the effect of Hsp104 on individual 
ApoB species.  Asterisk denotes p < 0.05.    
Figure 17. Hsp104 Affects Glycosylated and Non-Glycosylated ApoB Species. 
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A cycloheximide chase analysis was conducted in wildtype cells expressing ApoB and 
overexpressing Hsp104 (open circles) (N=12), hsp104∆ yeast expressing ApoB and Hsp104 
(closed circles) (N=16), and wildtype cells containing a vector control (open squares) (N=10), 
and hsp104Δ cells containing a vector control (closed squares) (N=10) that also expressed ApoB.  
After a temperature shifted to 37°C, samples were taken at the indicated times and lysates were 
processed for immunoblot analysis using anti-HA antibody to detect ApoB.  G6PD serves as a 
loading control. Examples of representative blots are shown below the data quantitation.   
Figure 18. Hsp104 Facilitates ApoB Degradation. 
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Lysates from wildtype yeast expressing ApoB were incubated in the presence or absence 
of an anti-ApoB antibody.  Following incubation with protein G coupled Sepharose beads, 
samples were washed and processed for immunoblot analysis using anti-HA, anti-Hsp104, anti-
Ssa1, anti-Sse1, and anti-rpL5 antibodies.  Ssa1, a cytosolic Hsp70, and Sse1, an Hsp110 
chaperone, have been previously shown to coimmunoprecipitate with ApoB.  rpL5, a ribosomal 
protein, serves as a negative control.   
Figure 19. Hsp104 Coimmunoprecipitates with ApoB. 
 89 
 in this pull-down assay when ApoB was present (Gusarova et al, 2001; Hrizo et al, 2007).   
Notably, there appears to be a larger molecular weight species present when ApoB was pulled 
down.  I hypothesize that this is an aggregate which remains at the interface of the separating and 
stacking gels during SDS-PAGE.  In contrast, rpL5, a ribosomal protein, was not observed after 
ApoB isolation. However, Hsp104 was also highly increased in the presence of ApoB, 
confirming that Hsp104 binds ApoB, perhaps in the context of a multi-chaperone complex. 
2.2.7 The Rvb Proteins Do Not Compensate For The Loss of Hsp104 
As Hsp104 has no obvious sequence homolog in humans, I was curious why this chaperone was 
required for ApoB degradation.  I was intrigued when a recent paper reported that human RuvBL 
family members could compensate for loss of yeast Hsp104 (Zaarur et al, 2015).  RuvBL1 and 
RuvBL2 are AAA+ DNA helicases but may also  function independently of the helicase activity, 
including for example in TATA binding activity, assembly of RNA polymerase II, and as a 
chaperone  (Gorynia et al, 2011; Jin et al, 2005; Kanemaki et al, 1997; Machado-Pinilla et al, 
2012; Putnam et al, 2001; Qiu et al, 1998; Shen et al, 2000; Tsaneva et al, 1993; Yamada et al, 
2001).  RuvBL1 and RuvBL2 are conserved in yeast and are known as Rvb1 and Rvb2.  These 
proteins also have DNA helicase activity and have been implicated in chromatin remodeling, 
snoRNP assembly, and DNA polymerase II assembly (Gribun et al, 2008; Jonsson et al, 2001; 
Kakihara & Houry, 2012; Lim et al, 2000; Shen et al, 2000).  When yeast lacking Hsp104 and 
overexpressing Rvb1 or Rvb2 were heat shocked, the cells were protected from heat stress 
induced death, indicating that overexpression can at least partially compensate for the loss of 
Hsp104 (Zaarur et al, 2015). 
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Based on these data, I was curious if the Rvb proteins could rescue the ApoB degradation 
defect in hsp104Δ cells.  To this end, I conducted cycloheximide chase assays in wildtype or 
hsp104Δ cells expressing ApoB and that either overexpressed Rvb2 or contained a vector 
control.  After cells were temperature shifted to 37°C, overexpression of Rvb2 unexpectedly did 
not restore ApoB degradation to wildtype levels (Figure 20).  These results suggest that the Rvb 
activity associated with the ability of the cells to compensate for survival after a severe heat 
shock is distinct from that required during ERAD.   
2.2.8 Hsp104 Does Not Affect ApoB Aggregation Propensity 
Based on the direct role of Hsp104 to facilitate the degradation of both an ER and cytoplasmic/ 
aggregated form of ApoB, I hypothesized that Hsp104 might maintain ApoB solubility prior to 
proteasomal degradation. To begin to test this hypothesis, I utilized a detergent solubility assay 
similar to that used by Zhao and colleagues (Zhao et al, 2013). This assay depends upon the 
observation that non-ionic detergents, such as dodecyl-maltoside (DDM), can solubilize 
membrane bound proteins but not aggregated proteins, while 1% SDS solubilizes proteins in 
both states.  To this end, ER derived microsomes were incubated with multiple concentrations of 
various detergents, including DDM, at 4°C.  Following centrifugation, supernatant (soluble) and 
pellet (insoluble) fractions were processed and subject to SDS-PAGE followed by western blot 
analysis.  Detergents analyzed include DDM, Triton X-100, Digitonin, sodium deoxycholate, (3-
((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) (CHAPS), and Urea.  Triton is a 
non-ionic detergent often used to extract proteins and permeabilize cell membranes.  Digitonin is 
a non-ionic detergent often used to water solubilize lipids and membrane proteins.  Sodium 
deoxycholate is a bile salt that is often used to lyse cells, solubilize cell membranes, and forms 
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mixed micelles with lipids and cholesterol.  CHAPS is a zwitterionic detergent used to solubilize 
proteins and under non-denaturing conditions or purify membrane proteins.  Urea denatures 
proteins by interfering with covalent bonds (Nicholls & Ferguson, 2013; Scientific; Scientific; 
Sigma-Aldrich).  This wide range of detergents was chosen to test ApoB aggregates in a variety 
of conditions, as the ApoB-containing aggregates may behave differently in various conditions.  
Digitonin was especially interesting due to its association with cholesterol. Concentrations were 
chosen based upon each detergent’s critical micelle concentration (CMC), which is the 
concentration when the solution experiences a dramatic change to form micelles (Tadros, 2013).  
The CMC can be altered based upon temperature, a protein’s intrinsic molecular properties and 
concentration.  The detergent concentration range was chosen by CMC/5, CMC, 5*CMC, 
10*CMC, and 30*CMC for each specific detergent.   
I first tested if there was a difference in ApoB solubility in the presence or absence of 
Hsp104 under non-stress conditions (Figure 21). Consistent with the cycloheximide chase assays 
conducted at 30°C, both ApoB species appeared in the supernatant with the highest concentration 
of all tested detergents in both wildtype and hsp104Δ yeast.  Similar to the carbonate results, the 
higher molecular weight species shifted more readily to the supernatant fraction than the lower 
molecular weight species.  Furthermore, there appeared to be no difference in ApoB solubility 
between the wildtype and hsp104Δ yeast.  Furthermore, I calculated the amount of soluble upper 
band and insoluble lower band for each detergent, using the concentration at which a majority of 
ApoB has been release.  In the wildtype strain, the glycosylated band is ~16% soluble in the 
presence of DDM, ~9% soluble in the presence of triton, ~46% soluble in the presence of 
digitonin, ~13% soluble in the presence of deoxycholate, and ~6% soluble in the presence of 
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A cycloheximide chase analysis was conducted on wildtype (closed circles) (N=9) and 
hsp104∆cells (open circles) (N=10) expressing ApoB and overexpressing Rvb2, and on wildtype 
(closed squares) (N=8) and hsp104Δ (open squares) (N=6) cells expressing ApoB and containing 
an empty vector control that were temperature shifted to 37°C.  At the indicated times, samples 
were taken and lysates were processed for immunoblot analysis using anti-HA antibody to detect 
ApoB.  G6PD serves as a loading control.  Examples of representative blots are shown below the 
data quantitation. 
Figure 20. Rvb2 Does Not Compensate For Loss of Hsp104. 
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 CHAPS.   The unglycosylated band is ~51% insoluble in the presence of DDM, ~53% insoluble 
in the presence of triton, ~27% insoluble in the presence of digitonin, ~45% insoluble in the 
presence of deoxycholate, and ~50% insoluble in the presence of CHAPS.  In the hsp104Δ strain, 
the glycosylated band is ~6% soluble in the presence of DDM, ~15% soluble in the presence of 
triton, ~33% soluble in the presence of digitonin, ~26% soluble in the presence of deoxycholate, 
and ~4% soluble in the presence of CHAPS.   The unglycosylated band is ~74% insoluble in the 
presence of DDM, ~55% insoluble in the presence of triton, ~36% insoluble in the presence of 
digitonin, ~47% insoluble in the presence of deoxycholate, and ~51% insoluble in the presence 
of CHAPS.   These results indicate that Hsp104 does not appear to affect ApoB aggregation 
propensity, at least under non-stress conditions.    
I was next curious if Hsp104 helped to maintain ApoB solubility in cells grown under 
heat stress conditions.  If this were true, then heat shocked strains lacking Hsp104 should contain 
higher levels of aggregated ApoB (and would be found in the pellet fraction) relative to wildtype 
cells.  To test this hypothesis, ER-derived microsomes made from ApoB-expressing wildtype 
and hsp104Δ yeast temperature shifted to 37°C were subjected to detergent solubility assays, as 
above, with multiple detergents (Figure 22). For wildtype cells expressing ApoB (left), the 
detergent solubility assay looked similar to those from non-temperature shifted cells, as both 
ApoB species accumulated in the supernatant fraction in every condition tested when the highest 
concentration of detergent was used.  Similarly, both species of ApoB shifted to the supernatant 
fraction in hsp104Δ yeast at the same concentrations of detergent as observed when microsomes 
from the wildtype cells were examined.  In addition, I again calculated the amount of soluble 
upper band and insoluble lower band for each detergent.  In the wildtype strain, the glycosylated 
band is ~5% soluble in the presence of DDM, ~10% soluble in the presence of triton, ~9% 
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soluble in the presence of digitonin, ~14% soluble in the presence of deoxycholate, ~5% soluble 
in the presence of CHAPS, and ~35% soluble in the presence of Urea.   The unglycosylated band 
is ~55% insoluble in the presence of DDM, ~73% insoluble in the presence of triton, ~73% 
insoluble in the presence of digitonin, ~68% insoluble in the presence of deoxycholate, ~61% 
insoluble in the presence of CHAPS and ~2% insoluble in the presence of Urea.  In the hsp104Δ 
strain, the glycosylated band is ~13% soluble in the presence of DDM, ~22% soluble in the 
presence of triton, ~12% soluble in the presence of digitonin, ~15% soluble in the presence of 
deoxycholate, 23% soluble in the presence of CHAPS, and ~26% soluble in the presence of 
Urea.   The unglycosylated band is ~59% insoluble in the presence of DDM, ~66% insoluble in 
the presence of triton, ~70% insoluble in the presence of digitonin, ~64% insoluble in the 
presence of deoxycholate, ~53% insoluble in the presence of CHAPS and ~3% insoluble in the 
presence of Urea.  These results suggest that Hsp104 does not play a role in maintaining ApoB 
solubility when it resides in the ER (higher molecular weight species) or is associated with the 
ER membrane (lower molecule weight species).  Therefore, Hsp104 does not affect aggregation 
propensity of ApoB.  
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Figure 21. ApoB Aggregation Propensity is Unaffected by Hsp104 Under Non-stress Conditions. 
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 ER derived microsomes were isolated from wildtype (left) and hsp104Δ (right) yeast 
expressing ApoB that were grown at 30°C.  Microsomes were mixed with the indicated 
concentrations of (A) dodecyl maltoside (DDM), (B) Triton X-100, (C) Digitonin, (D) sodium 
deoxycholate, and (E) (3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) 
(CHAPS) or 1% SDS and incubated on ice for 30 minutes.  Following centrifugation, 
supernatant (soluble) and pellet (insoluble) fractions were processed for immunoblot analysis 
using anti-HA and anti-Sec61 antibodies.  There appeared to be no difference in ApoB solubility 
between wildtype and hsp104Δ derived microsomes under any condition. 
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ER derived microsomes were prepared from wildtype (left) and hsp104Δ (right) yeast 
expressing ApoB that had been temperature shifted to 37°C.  Microsomes were mixed with the 
indicated concentrations of (A) dodecyl maltoside (DDM), (B) Triton X-100, (C) Digitonin, (D) 
sodium deoxycholate, (E) (3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) 
(CHAPS), and (F) Urea or 1% SDS and were incubated on ice for 30 minutes.  Following 
centrifugation, supernatant (soluble) and pellet (insoluble) fractions were processed for 
immunoblot analysis using anti-HA and anti-Sec61 antibodies. 
Figure 22. Hsp104 Does Not Affect ApoB Aggregation Propensity Under Stress Conditions. 
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2.2.9 Hsp104 Affects ApoB Retrotranslocation 
Although Hsp104 does not appear to maintain the solubility of ApoB in microsomes, the fact that 
this AAA+ ATPase can extract aggregated proteins through the central cavity suggests that it 
might directly function with Cdc48 to retrotranslocate ApoB (Gates et al, 2017; Heuck et al, 
2016; Yokom et al, 2016).  I explored this question by using an in vitro retrotranslocation assay, 
with the help of Mike Preston, while he was a graduate student in our lab.  This assay 
investigates the ability of any membrane protein expressed in yeast and that resides in the ER to 
be ubiquitinated and retrotranslocated (Buck et al, 2016; Nakatsukasa et al, 2008).  In this assay, 
ER derived microsomes, yeast cytosol, an ATP regenerating system, and 125I-ubiquitin are 
combined to allow for ubiquitination.  Supernatant and pellet samples are separated by 
centrifugation and then the ERAD substrate in each fraction is subject to immunoprecipitation.  
By quantifying the amount of material in the supernatant and pellet fractions, one can determine 
how efficiently a ubiquitinated protein is retrotranslocated from the membrane based upon the 
presence of 125I-ubiquitin that has been conjugated to the substrate. 
Using this assay, I tested ApoB retrotranslocation.  ER-derived microsomes from 
wildtype and hsp104Δ yeast that expressed ApoB and temperature shifted to 37°C were 
combined with yeast cytosol, an ATP regenerating system, and 125I-ubiquitin.  Following 
centrifugation immunoprecipitation, samples were washed, and subjected to SDS-PAGE 
followed by western blot or phosphorimager analysis.  Following a temperature shift to 37°C, I 
found that ubiquitinated ApoB was retrotranslocated to a somewhat lower but reproducible 
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degree when Hsp104 was absent (Figure 23).  This result suggests that Hsp104 may help 
facilitate ApoB degradation by directly aiding ApoB retrotranslocation.  
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ER derived microsomes prepared from wildtype (N=10) (grey bar) and hsp104Δ (N=10) 
(striped bar) yeast expressing ApoB (temperature shifted to 37°C) were subjected to an in vitro 
retrotranslocation assay.  Reactions containing microsomes, yeast cytosol, an ATP regenerating 
system and 125I-ubiquitin were conducted at 37°C for 45 minutes.  Control reactions lacked the 
ATP regenerating system.  The reactions were quenched, centrifuged, and the supernatant and 
pellet fractions immunoprecipitated overnight using anti-ApoB antibody and protein G 
conjugated Sepharose beads.  Following washing, samples were subjected to duplicate SDS-
PAGE following by western blot or phosphorimage analysis.  P value = 0.0197. 
Figure 23.The Retrotranslocation of Ubiquitinated ApoB is Somewhat Lower in the Absence of Hsp104. 
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2.3 DISCUSSION 
As described in this chapter, I developed a new expression system to investigate the fate of 
ApoB in the model yeast, Saccharomyces cerevisiae.  This new system allows for the controlled 
induction of ApoB through the use of β-estradiol and a chimeric “GEV” transcription factor.  
Only small amounts of β-estradiol (< 1 µM) were required to induce ApoB protein production, 
consistent with previous reports that GEV is saturated between 100 nM and 1 µM β-estradiol 
(McIsaac et al, 2011).  ApoB appears as two bands via western blot, a larger, glycosylated 
molecular weight species and a smaller, non-glycosylated molecular weight species in both the 
galactose inducible (Grubb et al, 2012; Hrizo et al, 2007) and β-estradiol inducible expression 
systems (this study). 
I hypothesize that the lower molecular weight species corresponds to an alternative start 
site being used to make the ApoB protein and that this protein lacks a signal sequence.  Even 
though the full length protein appears to be synthesized and possesses features consistent with it 
being a translocated form of ApoB, DNA sequence analysis of the ApoB29 plasmid suggested 
the ApoB protein should not have been fully translated (Figure 10). To address this issue, I have 
attempted to make additional mutations in the ApoB expression plasmid.  One mutation alters 
the predicted methionine for the alternative start site to alanine using the QuikChange XL II site 
directed mutagenesis kit (Agilent).  Although I succeeded in introducing this mutation, I could 
only sequence the N-terminal 60% of the ApoB29 coding sequence.  Furthermore, this plasmid 
was unable to sustain the growth of yeast on selective media (data not shown).  Additional 
attempts to create another plasmid with the site directed mutagenesis kit led to the construction 
of plasmids that could not be recovered from either yeast or E.coli.  Recently, I  created an ApoB 
plasmid that lacks the signal sequence.  Initial investigations with this construct confirm the role 
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of the proteasome and Hsp104 on the degradation of the lower molecular weight species of 
ApoB.  Thus, the data in thesis on the lower molecular weight form have been validated.   
Although the current ApoB plasmid may contain mutations (see below), I propose that 
this is still a valid model to investigate ApoB regulation and believe that bona fide ApoB is still 
being synthesized for a variety of reasons.  First, I observe the correct predicted molecular 
weight for the ApoB29 protein.  Next since ApoB contains a C-terminal HA tag and is detectable 
using anti-HA antibody, the HA tag must still be translated in frame.  Furthermore, the protein 
can be immunoprecipitated using a commercial anti-ApoB antibody.  Additionally, the higher 
molecular weight species is glycosylated and is carbonate extractable, indicating that it is, at least 
partially, able to enter the ER, as expected for ApoB.  Finally, we have previously used this 
ApoB29 construct to identify factors in yeast that affect ApoB biogenesis and have confirmed 
these results in mammalian cells (Grubb et al, 2012; Hrizo et al, 2007).  It seems unlikely that we 
would have obtained these results if the protein was completely irrelevant.  It is also formally 
possible that the sequencing results are incorrect, as sequencing was only conducted once and 
data were obtained from only one DNA strand.  As we have had trouble using this ApoB29 
construct for cloning, it would not be surprising if sequencing issues arose from improper 
priming.         
I used the new ApoB29 expression system to determine if the protein interacts with lipid 
droplets using a large scale lipid droplet isolation.  Even though lipid droplets were isolated, 
ApoB did not reside in this fraction.  Furthermore, cycloheximide chase assays conducted by a 
previous graduate student, Sarah Grubb, in lipid droplet deficient yeast using the galactose 
inducible system showed ApoB degradation was unaffected compared to the wildtype strain 
(Grubb, 2013).  Taken together, ApoB does not interact with lipid droplets in yeast and its 
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degradation is independent of these species, which is consistent with reports that lipid droplets 
are not required for ERAD in yeast (Olzmann & Kopito, 2011; To et al, 2017).   
Previously, ApoB crescents were observed in Huh7 cells (Ohsaki et al, 2006).  This cell 
type may not be the most representative model for ApoB, as Huh7 cells do not normally secrete 
ApoB.  Furthermore, the ApoB crescents may not specifically localize to lipid droplets but 
interact near the surface of the lipid droplets, as the outer leaflet of the ER is continuous with 
lipid droplets in yeast and in certain mammalian cells (Jacquier et al, 2011; Wilfling et al, 2013).  
In fact, using confocal microscopy ApoB was observed to be restricted to the ER membrane, 
which was in contact with the lipid droplet surface but not with the lipid droplet itself (Gao & 
Goodman, 2015; Suzuki et al, 2012).  Additionally, Ohsaki and coworkers could eliminate this 
localization by inhibiting the MTP complex using drugs or siRNA, suggesting that only lipidated 
ApoB localized to these crescents (Ohsaki et al, 2008).  As yeast lack an MTP complex, the 
ApoB protein is probably not lipidated, which may account for the lack of lipid droplet 
localization.  Interestingly, a recent report implicated the E3 ubiquitin ligase, Doa10, as a 
mediator of ER protein selection into lipid droplets (Ruggiano et al, 2016).  Doa10 targeted 
proteins that associate with the membrane via a “hairpin” and that localize to both the ER and 
lipid droplet membranes.  The enzyme was responsible for degrading the ER pool of these 
proteins, thereby restricting these substrates to lipid droplets.  Since ApoB is a Hrd1 substrate 
and is unaffected by deletion of Doa10, these data are consistent with ApoB being restricted 
from lipid droplets.   
I hypothesized that Hsp104 affects ApoB degradation by preventing ApoB from 
aggregating once it is retrotranslocated but before it is targeted for proteasome-mediated 
degradation.  I observed that Hsp104 facilitates ApoB degradation under heat stress but not 
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under non-stress conditions via cycloheximide chase assays.  Degradation was accelerated upon 
over expression of Hsp104.  These results were intriguing as ApoB29 is the first established 
ERAD substrate demonstrated to be an Hsp104 substrate.  To show that this effect was direct, I 
determined that Hsp104 binds ApoB.  I also observed Hsp70 in the coimmunoprecipitations.  
Since Hsp104  interacts with Hsp70 and Hsp40 once it has removed protein substrates from 
aggregates, Hsp70 also interact with ApoB and Hsp104 to prevent ApoB aggregation (Glover & 
Lindquist, 1998; Shorter, 2017).       
Based on the established role of Hsp104 as a protein disaggregase, I first hypothesized 
that Hsp104 affects the aggregation propensity of ApoB (Zolkiewski et al, 2012).  Since Hsp104 
is a cytosolic protein, it most likely interacts preferentially with the cytosolic form of ApoB, i.e. 
the lower molecular weight form that fails to enter the ER.  This was supported by quantifying 
the effect of Hsp104 on each band.  As hypothesized, the non-glycosylated form had a much 
stronger dependence on Hsp104 for degradation than the glycosylated form. However, there was 
no apparent difference in ApoB aggregation in the presence or absence of Hsp104 under stress or 
non-stress conditions, as assessed using various detergents.  Therefore, I next hypothesized that 
Hsp104 may affect ApoB’s retrotranslocation efficiency.  As hypothesized, in the absence of 
Hsp104 ApoB is retrotranslocated less efficiently to a small but reproducible degree.  Although 
these data are preliminary, they lead to two potential models for how Hsp104 might affect ApoB 
degradation.  In one view, Hsp104 may help keep ApoB in a retrotranslocation competent state 
and facilitate its retrotranslocation.  ApoB forms large cytosolic loops that may interact with 
Hsp104.  Thus Hsp104, in combination with Hsp70, may protect ApoB such that Cdc48 can 
more easily associate with it to facilitate retrotranslocation. The chaperone could also potentially 
hold ApoB in a position that makes it more Hrd1 accessible, which facilitates ubiquitination.  
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Alternatively, Hsp104 might work cooperatively with Cdc48 to directly drive retrotranslocation.  
Through its AAA+ domains, Hsp104 couples ATP hydrolysis to protein disaggregation by 
translocating protein substrates through the central cavity (Gates et al, 2017; Heuck et al, 2016; 
Yokom et al, 2016).  Perhaps, Hsp104 can provide additional force with Cdc48 to move ApoB 
from the translocon.  In turn, the disaggregase activity of Hsp104 might be more important to 
degrade the detergent insoluble untranslocated (i.e. lower molecular weight) form of ApoB.  The 
action of Hsp104 as a cytoplasmic protein disaggregase is well established (Glover & Lindquist, 
1998; Parsell et al, 1991; Shorter, 2011).   
Surprisingly, the Hsp104 disaggregase is not conserved in metazoans.  This poses the 
question as to what is the holdase for ApoB is in mammalian cells.  I was intrigued when the 
conserved Rvb proteins were reported to functionally compensate for loss of Hsp104 in heat 
stressed cells (Zaarur et al, 2015).  However, overexpression of Rvb2 did not affect ApoB 
protein degradation rates in yeast that lack Hsp104.  This may be because the Rvb proteins are 
primarily associated with nuclear proteins and nuclear complexes, including those involved in 
snoRNP regulation, chromatin remodeling, RNA polymerase II assembly, and DNA damage 
responses (Gorynia et al, 2011; Gribun et al, 2008; Kakihara & Houry, 2012; Matias et al, 2015; 
Putnam et al, 2001).  Furthermore, at a recent conference Dr. Walid Houry reported that the Rvb 
proteins form nuclear foci upon cellular stress (personal communication).  As ApoB is a 
cytosolic protein, the Rvb proteins may not be accessible to ApoB to affect degradation, yet it is 
still able to rescue a nuclear defect in hsp104Δ cells.  It has also been proposed that Hsp110, 
Hsp70, and Hsp40 cooperate to serve this holdase and disaggregase function in mammalian cells 
(Mattoo et al, 2013; Rampelt et al, 2012; Shorter, 2011; Torrente & Shorter, 2013).  This 
complex preferentially refolded amorphous aggregates over amyloid fibrils, but folding was 
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slower in comparison to Hsp104-mediated protein refolding (also see Chapter 3).  Current efforts 
in the laboratory are examining whether members of the mammalian Hsp70, Hsp40, and Hsp110 
complex affect ApoB stability and act as disaggregases.   
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3.0  CONCLUSIONS 
CAD is the leading cause of death worldwide and is characterized by the presence of 
atherosclerotic plaques, caused by an overabundance of circulating LDLs and cholesterol.  The 
gold standard to combat CAD is the use of statins, which block the committed step during 
cholesterol synthesis.  However due to side effects, nearly one third of all users stop the 
treatment.  Alternative therapies recently have focused on regulators of cholesterol synthesis, 
delivery, or degradation.  One of these regulators is ApoB, which is the essential structural 
component of LDL.  Mipomersen is the first approved anti-sense oligonucleotide that targets 
ApoB to control cholesterol levels in humans.  But based on limitations to the use of this drug 
(see Chapter 1), there must be other ways to regulate ApoB levels, in addition to targeting 
cholesterol or ApoB levels specifically.  I identified one such factor, Hsp104, which promotes 
ApoB degradation.  Hsp104 is a molecular chaperone holdase and a disaggregase that appears to 
modestly affect ApoB’s retrotranslocation efficiency.  Unfortunately, Hsp104 is not conserved in 
humans.  This begs the question of what factor might perform an equivalent function for Hsp104 
in humans.  In this chapter, I suggest candidate factors that may serve as a holdase and 
disaggregase for ApoB in human cells. 
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3.1 HSP110 AND HSP40 
For unknown reasons, metazoans do not have a homolog of the Hsp104 disaggregase.  To 
compensate for the lack of this enzyme, it has been proposed that Hsp110, Hsp70, and Hsp40 act 
cooperatively to disaggregate proteins (Mattoo et al, 2013; Rampelt et al, 2012; Shorter, 2011; 
Shorter, 2017).  Hsp70 is an ATPase associated with protein folding.  Its ATPase activity is 
stimulated by Hsp40, and Hsp110 acts as a nucleotide exchange factor for Hsp70.  However, it 
was observed that Hsp110 can also function as an ATP-dependent unfoldase and also has 
chaperone activity on its own, which is sufficient to prevent substrate misfolding and aggregation 
(Dragovic et al, 2006; Polier et al, 2008; Raviol et al, 2006; Ziegelhoffer et al, 1995).  In yeast, 
one of the cytoplasmic Hsp70s is Ssa1, and its activity is stimulated by the Hsp40, Ydj1, as well 
as by Sse1, an Hsp110 family member.  This conserved trio of proteins has the ability to 
disaggregate proteins in yeast, although the disaggregase activity was slow compared to Hsp104, 
at least under the conditions of this in vitro experiment (Shorter, 2011).   
In cells, Hsp110 may serve as the holdase and further facilitate disaggregase activity.  In 
yeast, Hsp110 helps to facilitate prion propagation and may localize to stress foci (Escusa-Toret 
et al, 2013; Spokoini et al, 2012).  Mammalian Hsp110 has also been shown to assist in the 
removal of aggregated proteins (Eroglu et al, 2010; Olzscha et al, 2011; Yamashita et al, 2007).  
We previously investigated the role of Sse1 on ApoB degradation using our galactose inducible 
yeast expression system (Hrizo et al, 2007).  In yeast, we found the ApoB degradation was faster 
in the absence of Sse1 and that ApoB coimmunoprecipitated with Sse1 and Ssa1.  In mammalian 
cells, ApoB secretion was increased when Hsp110 was overexpressed.  This result suggests that 
Sse1 interacts with ApoB to act as a holdase and in mammals the conserved protein promotes its 
maturation and secretion.  However, the chaperone/holdase activity of Sse1 only requires the C-
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terminal domain in vitro and it has been shown that the N-terminal ATP binding domain of Sse1 
is required to rescue the growth of a temperature sensitive mutant form of Hsp40 when 
overexpressed (Goeckeler et al, 2002).  This result may indicate that the chaperone activity of 
Sse1 alone is not sufficient to serve as a holdase.   
Alternatively, Hsp40 could perform the holdase function for ApoB.  This is an intriguing 
target as it has been shown that Hsp40 in mammals is a potent disaggregation machine 
(Nillegoda et al, 2015).  Working in pairs, the Hsp40s (when combined with Sse1 and Ssa1) 
could disaggregate and refold a heat denatured luciferase protein with similar efficiency as the 
Hsp104 system.       
Based on these and other data, we have recently begun to investigate if Hsp40 also affects 
ApoB degradation and aggregation.  During her rotation in our lab when I served as her mentor, 
another graduate student, Deepa Kumari, observed that ApoB degradation was significantly 
slowed in a yeast strain containing a temperature sensitive mutant form of Ydj1.  Most 
interestingly , we observed only the lower molecular weight species of ApoB in the temperature 
sensitive Ydj1strain, which we hypothesize is an untranslocated form of ApoB.  Ydj1 has been 
previously shown to be required for the translocation of another protein into the yeast ER, 
prepro-alpha factor (Becker et al, 1996).  We hypothesize that Ydj1 may play a dual role, 
assisting both in translocation of ApoB and in the subsequent degradation of the protein via 
ERAD.  Since joining our lab, Deepa has begun pulse-chase experiments in rat hepatic McArdle 
RH7777 cells to see if the Ydj1 homolog, DNAJA1, affects ApoB stability, maturation, or both.  
Hsp40s could be regulators of ApoB function, if the chaperone indeed helps to promote ApoB 
translocation and degradation when lipids are depleted.   
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3.2 GET COMPLEX 
Another possible candidate for an ApoB holdase function is the Guided Entry of Tail-anchored 
(GET) proteins complex, which help with the membrane insertion of tail-anchored proteins.  
Tail-anchored proteins are characterized by the presence of a C-terminal transmembrane domain 
which anchors the protein into the ER membrane after their complete synthesis (Chartron et al, 
2012; Denic et al, 2013).  These transmembrane domains must be shielded from the aqueous 
environment of the cell post-translationally and before insertion, which is performed by a 
complex consisting of Sgt2, Get4, and Get5 in yeast.  Subsequently, the tail-anchored protein is 
shuttled to Get3 and then is inserted into the ER membrane by the integral membrane proteins 
Get1 and Get2.  The Sgt2, Get4, Get5 complex could potentially act as a holdase for ApoB, 
serving a similar function as they do with tail-anchored proteins, except that in this case a 
hydrophobic protein is protected as it leaves the ER.  In addition, the mammalian homologs of 
this complex have been shown to interact with retrotranslocated proteins during ERAD to help 
facilitate degradation (Hessa et al, 2011; Minami et al, 2010; Wang et al, 2011). Interestingly, the 
function of Sgt2 has been linked to Hsp104 in yeast.  Specifically, the curing of yeast prions 
performed by Hsp104 could be reversed by overexpressing Ssa1, an Hsp70, and Sgt2 was the 
switch to increase targeting of Ssa1 to the prion (Kiktev et al, 2012).   
With the help of an undergraduate in the Brodsky lab, Andrew Schulz, we have recently 
begun investigating if the Get Complex affects ApoB stability using our β-estradiol inducible 
expression system.  Andrew examined if the absence of Sgt2 affects ApoB stability using 
cycloheximide chase assays.  He observed that ApoB was degraded faster in the absence of Sgt2 
compared to the rate in wildtype cells, indicating that Sgt2 plays a role in stabilizing ApoB.  We 
are currently investigating the effect of Sgt2 deletion on another ERAD substrate, Ste6p*, to 
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determine if this effect is applicable to ERAD substrates besides ApoB.  We are additionally 
creating a plasmid that will be used to overexpress Sgt2.  I predict the introduction of this 
expression vector will slow ApoB degradation in yeast.  In the future, we intend to investigate if 
the human homolog, SGTA, as well as other members of the GET complex affect ApoB 
degradation in mammalian cells through pulse chase experiments.   
3.2.1 The Bag6 Complex 
In humans, the Sgt2, Get3, Get4 complex consists of SGTA, UBL4A, and Trc35 but GET 
complex function also requires an additional cofactor, Bag6.  Bag6 is a member of the Bag 
family of proteins, which are characterized by the presence of a C-terminal BAG domain which 
mediates interaction with Hsp70 (Casson et al, 2016; Kabbage & Dickman, 2008).  Bag6 helps 
facilitate transfer of tail anchored proteins from SGTA to Trc40, the homolog of Get3.  Bag6 was 
subsequently shown to help facilitate the degradation of ubiquitinated proteins and to have in 
vitro chaperone activity.  Bag6 appears to recognize exposed hydrophobic regions in proteins 
(Hessa et al, 2011; Minami et al, 2010; Wang et al, 2011).  Furthermore, Bag6 has been 
implicated in retrotranslocation of another misfolded, glycosylated ERAD substrate, TCRα 
(Claessen & Ploegh, 2011).  As ApoB is also a ubiquitinated glycosylated protein with 
hydrophobic domains, perhaps Bag6 could serve a similar function for ApoB during the 
degradation of ApoB. 
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3.3 OTHER POTENTIAL TARGETS FOR TREATING CORONARY ARTERY 
DISEASE 
As illustrated by drugs that target PSCK9 (see Chapter 1), current investigations into treating 
CAD without modulating ApoB can be extremely effective.  Another way this may be 
accomplished is by targeting the assembly of the MTP complex.  One drug, Lomitapide, prevents 
the action of the MTP complex (Cuchel et al, 2013).  But since the MTP complex requires the 
assembly of the M subunit with a PDI, perhaps a drug that prevents the formation of the complex 
or the activity of PDI would also inhibit vLDL formation.  Another potential target might be 
TANGO/TALI, which has been proposed to recruit lipids to ER exit sites to facilitate pre-vLDL 
formation (Santos et al, 2016).  If these factors help to assemble pre-vLDLs, then perhaps in their 
absence (possibly by siRNA) circulating vLDLs and cholesterol would be reduced.  Overall, 
there are a variety of factors that may serve as new targets for treatment of CAD.   
3.4 CONCLUDING REMARKS 
A great deal of effort has been put forth into understanding the underlying causes of 
cardiovascular diseases, generating a wealth of information about risk factors, pathology, factors 
that regulate the progression of CAD, and treatments, both approved for human use and in 
clinical trials.  Understanding the basic biological causes of CAD has proven to be the one of the 
most exciting areas of research but also one of the most challenging due in part to cholesterol’s 
important biological functions.  As the field moves forward, it is becoming increasingly clear 
that targeting the factors that regulate cholesterol synthesis is vital for treatment of CAD.  This 
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has led to the development of new treatments, such as PSCK9 antibody therapy, which have the 
potential to rival statins in their effectiveness for treating CAD.  It is important to continue to 
pursue alternative treatments as individuals respond differently to various treatments.  It is my 
hope that my investigations into the degradation pathway of ApoB will also contribute to 
therapeutics for CAD.   
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APPENDIX A 
A.1 INVESTIGATION OF THE ROLES OF POTENTIAL TRANSLOCON 
REGULATORS ON APOLIPOPROTEIN B DEGRADATION 
A previous student in the Brodsky lab, Dr. Sarah Grubb, was interested in factors that could 
potentially regulate the endoplasmic reticulum associated degradation (ERAD) of ApoB.  One 
focus of her work was on factors that may affect the interaction between the Sec61 translocon 
and ApoB.  ApoB is known to interact with Sec61 and then retrotranslocate to the cytoplasm for 
degradation (Cardozo et al, 2002; Chen et al, 1998; Fisher et al, 2008; Mitchell et al, 1998; 
Pariyarath et al, 2001).  During my rotation in the Brodsky lab I was mentored by Dr. Grubb, and 
I investigated two potential translocon regulators, Ysy6 and YKL207w (Grubb, 2013).  Ysy6 was 
first identified in an E.coli screen for mutations that suppress a secretion defect of SecY, the 
bacterial homolog of Sec61α, (Sakaguchi et al, 1991).  Ysy6 was also identified as the yeast 
homolog of RAMP4 (ribosome associated membrane protein 4), which is proposed to help 
mediate protein translocation (Schroder et al, 1999).  YKL207w, which has subsequently been 
renamed ECM3, is a member of the ER membrane complex (ERM), which facilitates protein 
folding, and results in upregulation of the unfolded protein response (Jonikas et al, 2009; Richard 
et al, 2013).  To examine if these putative translocon regulators affected ApoB, I conducted 
cycloheximide chase assays in wildtype yeast and in yeast lacking Ysy6 and YKL207w at 30°C 
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using the galactose inducible expression system (Hrizo et al, 2007).  Samples were TCA 
precipitated and to monitor ApoB levels western blot analysis was used.  However, the 
degradation of ApoB was unaffected in the absence of either of these potential translocon 
regulators, indicating that these proteins do not affect ApoB ERAD (Grubb, 2013).   
Dr. Grubb investigated another conserved family of proteins, the Yeast endoplasmic 
reticulum transmembrane (Yet) proteins, which she also hypothesized, may affect the ERAD of 
ApoB.  The Yet proteins are a conserved family of integral membrane proteins thought to assist 
in membrane protein synthesis (Annaert et al, 1997; Ladasky et al, 2006; Paquet et al, 2004; 
Schamel et al, 2003; Wilson & Barlowe, 2010).  She determined that ApoB degradation was 
slowed in yet2Δ and yet3Δ yeast while ApoB stability was unaffected in the yet1Δ strain (Grubb, 
2013).  In collaboration with the Fisher laboratory at the New York University School of 
Medicine, she went on to show that overexpression of Bap31, the mammalian homolog of Yet3, 
also affected ApoB degradation and secretion in mammalian cells.  One of the remaining 
unanswered questions was how these proteins are regulating ApoB.   
A.2 MATERIALS AND METHODS 
A.2.1 Degradation Assays 
Conducted as described in previous section 2.1.3 
 
 117 
A.2.2 Denaturing Coimmunoprecipitation Assay 
For ApoB29 protein production, plasmid pSLW1-B29 was used (Hrizo et al, 2007).  For copper-
inducible myc-tagged ubiquitin protein production, plasmid pKN31 was used (Nakatsukasa et al, 
2008).   
Cells were grown overnight in synthetic minimal media lacking uracil and histidine 
supplemented with 2% glucose at 30°C.  Cells were diluted back in the same media and grown 
until log phase (OD600 = 0.4-0.6).  ApoB29 production was induced using 300 nM β-estradiol for 
2 hours at 30°C.  A total of 150 ODs were harvested and resuspended in synthetic minimal 
media lacking uracil and histidine supplemented with 2% glucose and 300 nM β-estradiol to a 
concentration of 3 OD600/mL.  Next, the cells were incubated for 15 minutes at 30°C and 
ubiquitin was induced using 100 µM copper sulfate for 2 hours at 30°C.  Cells were harvested 
and stored at -80°C.   
 Cells were resuspended in 500µL IP Extract Buffer (50 mM Tris, pH7.4, 0.5% SDS, 1 
mM EDTA) supplemented with protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 0.5 µg/mL 
pepstatin A), c0mplete EDTA free protease inhibitor cocktail (Roche), and 10 mM NEM.  The 
cells were then lysed on a Vortex mixer 5 times for 30 seconds each round, with 30 second 
incubations on ice in between each agitation.  The resulting cell lysate was centrifuged for 5 
minutes at 13,000 rpm.  The supernatant was saved and 10% was reserved for the “input”.  The 
remaining lysate was diluted to 1.5 mL using IP dilution buffer (60 mM Tris, pH 7.4, 190 mM 
NaCl, 2.25% Triton X-100, 6 mM EDTA) supplemented with protease inhibitors, protease 
inhibitor cocktail, and 10 mM NEM.  Next, the samples were incubated with HA-conjugated 
beads or Sepharose 6B beads overnight (~20 hours) at 4°C with rotation.  The next day, samples 
were centrifuged for 2 minutes at 5000 rpm at 4°C and washed 3 times in IP Wash buffer (50 
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mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.2% SDS, 5 mM EDTA) supplemented 
with protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 0.5 µg/mL pepstatin A), c0mplete 
EDTA free protease inhibitor cocktail, and 10 mM NEM.  The samples were then washed 3 
times in Urea Wash buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.2% SDS, 5 
mM EDTA, 2 M Urea) supplemented with protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 
0.5 µg/mL pepstatin A), c0mplete EDTA free protease inhibitor cocktail, and 10 mM NEM.  
Samples were washed twice in TEA (50 mM Tris, pH7.4, 150 mM NaCl, 5 mM EDTA) 
supplemented with protease inhibitors (1 mM PSMF, 1 µg/mL leupeptin, 0.5 µg/mL pepstatin 
A), c0mplete EDTA free protease inhibitor cocktail, and 10 mM NEM and resuspended in TCA 
sample buffer (80 mM Tris, pH8, 8 mM EDTA, 120 mM DTT, 3.5% SDS, 0.29% glycerol, 
0.08% Tris base, 0.01% bromophenol blue).  The input material was TCA precipitated and all 
samples were heated at 37°C for 20 minutes followed by duplicate SDS polyacrylamide gel 
electrophoresis and western blots.  One western blot was immunoblotted using HRP-conjugated 
anti-HA antibody (Roche Applied Sciences, 3F10) and the duplicate western blot was 
sandwiched between thick Wattman paper and boiled in a waterbath for 1 hour.  The boiled 
western blot was blocked in fetal bovine serum containing triton and ubiquitin was detected with 
α-myc (Cell Signaling) or α-Ubiquitin (FL76) (Santa Cruz) antibodies and visualized using 
SuperSignal West Femto kit.    
A.3 RESULTS AND DISCUSSION 
I hypothesized that the Yet proteins may affect the ability of ubiquitin to be conjugated onto 
ApoB.  Ubiquitin conjugation is a series of enzymatic reactions that attach a ubiquitin moiety 
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onto a substrate protein through an E1 activating enzyme, an E2 conjugating enzyme, and an E3 
ubiquitin ligase (see section 1.4) (Preston & Brodsky, 2017).  I investigated this hypothesis 
through the use of denaturing immunoprecipitations (IP).  By pulling down ApoB with anti-HA 
conjugated or Sepharose beads, I could investigate the potential change in ubiquitination level by 
western blot analysis when the Yet genes were deleted.  I first optimized conditions using a 
mutated version of Sterol 6 (Ste6p*), which is an ERAD substrate, as a control for both IP 
conditions and ubiquitin detection, as Ste6p* has been previously shown to acquire detectable 
ubiquitin levels via this method (Nakatsukasa et al, 2008).  Indeed, I was able to 
coimmunoprecipitate Ste6p* and ubiquitin was detected (Figure 24) as compared to the 
Sepharose bead control.  
I next investigated whether ApoB was ubiquitinated using the conditions established with 
Ste6p*. Before conducting the IP, I screened colonies for expression levels of ApoB.  Four 
colonies from BY4742 (wildtype), yet1Δ, yet2Δ, yet3Δ, and yet1,2,3Δ yeast expressing ApoB 
protein, induced using the β-estradiol system, (see section 2.2.1) were harvested.  Following 
TCA precipitation and western blotting, colonies with near equal expression were chosen for 
subsequent use (data not shown).  Next, I grew yeast containing copper inducible myc-tagged 
ubiquitin and either the empty vector or the ApoB expression vector in BY4742, yet1Δ, yet2Δ, 
yet3Δ, and yet1,2,3Δ yeast strains and subsequently induced the myc-tagged ubiquitin with 100 
µM copper.  Cells were lysed under denaturing conditions and IPs were conducted overnight 
with either HA-conjugated or Sepharose 6B beads.  Samples were washed followed by SDS-
PAGE and western blotting for both ApoB and ubiquitin (Figure 25).  ApoB was enriched in the 
IP in the lanes in which ApoB was expressed and incubated with α-HA conjugated beads as  
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Denaturing immunoprecipitations were conducted in pdr5Δ yeast expressing Ste6p* and 
overexpressing myc-tagged ubiquitin incubated with either HA-conjugated or Sepharose 6B 
beads.  One hundred fifty OD600 equivalents of yeast expressing Ste6p* and myc-tagged 
ubiquitin were harvested and resuspended in IP Extract buffer (see section A1.2).  Cells were 
lysed on a vortex mixer and lysate was immunoprecipitated overnight with either HA conjugated 
or Sepharose 6B beads. Following washing, samples were subjected to SDS-PAGE and western 
blotting using anti-HA or anti-Ubiquitin antibodies.  
Figure 24. Detection of Ubiquitin Levels of Ste6p*. 
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Figure 25. Preliminary Investigation of ApoB Ubiquitination Levels. 
Denaturing immunoprecipitations were conducted in wildtype (BY4742), yet1Δ, yet2Δ, 
yet3Δ, and yet1,2,3Δ yeast expressing ApoB or containing a vector and myc-tagged ubiquitin 
expression vectors.  IP conditions were conducted as in Figure 24. Following washing, samples 
were subjected to SDS-PAGE and western blotting using anti-HA and anti-ubiquitin antibodies.   
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compared to the Sepharose bead control or vector alone.  However, variable amounts of ApoB 
were pulled down during the IP, even though these colonies were screened for equal expression 
prior to experimentation.  Additionally, ubiquitination levels above the vector control were 
difficult to detect for ApoB. 
I next wanted to investigate the stability of ApoB in the absence of the Yet proteins using 
my new β-estradiol inducible expression system (see section 2.2.1) as Dr. Grubb had identified 
these translocon regulators using our galactose inducible expression system.  Since this is a less 
stressful induction system due to the lack of carbon source switching, I was curious as to how the 
Yet proteins affected ApoB.  I predicted that the Yet proteins effect on ApoB stability would be 
similar regardless of whether the galactose inducible or β-estradiol inducible expression system 
was used, since I had not observed differences in stability between the expression systems in 
other experiments (see section 2.2.1).  ApoB protein was induced in wildtype, yet1Δ, yet2Δ, 
yet3Δ, and yet1,2,3Δ yeast strains followed by cycloheximide chase assays conducted at 30°C.  
Samples were subsequently TCA precipitated and proteins were subjected to western blot 
analysis (Figure 26).  Surprisingly, there appeared to be no difference in degradation rates for 
ApoB in the various strains.   
If these experiments were pursued further, additional controls would be included.  For the 
IPs, I have recently identified an anti-ApoB antibody (EMD Millipore) that appears to give a 
more reliable ApoB IP.  The denaturing IPs could be repeated with this antibody.  Perhaps this 
would produce a more robust and reproducible level of precipitation, which would allow me to 
determine potential differences in the ubiquitination state of ApoB.  Additionally, the 
cycloheximide chase assays could be repeated at 37°C, which would be a stressful condition on 
the cells.  In addition to the yeast result, Dr. Grubb also showed that Bap31 affected ApoB 
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degradation in mammalian cells.  However, this leaves the puzzle of why the Yet proteins do not 
affect ApoB stability in the β-estradiol inducible system.  Perhaps as this system is less stressful 
on the yeast cells compared to galactose, the Yet proteins are not as important for regulating 
ApoB.  By conducting the cycloheximide chase assays under stressful conditions, such as a 
temperature shift, perhaps we could recapitulate the requirement for the Yet proteins for ApoB 
degradation.      
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Figure 26. ApoB Appears Unaffected in Strains Lacking the Yet Proteins Where the β-estradiol Inducible 
Expression System Was Used. 
Cycloheximide chase assays were conducted at 30°C in BY4742 (open circles) (N=4), 
yet1Δ (closed circles) (N=4), yet2Δ (open squares) (N=4), yet3Δ (closed squares) (N=3), and 
yet1,2,3Δ (diamonds) (N=2) yeast expressing ApoB.  Samples were TCA precipitated and 
proteins were subjected to western blot analysis using anti-HA to detect ApoB.  G6PD serves as 
a loading control.  
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